(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/067621 A1

(51) International Patent Classification:
A01N 39/04 (2006.01) *A01N 43/54* (2006.01)
A01N 43/40 (2006.01) *A01N 57/20* (2006.01)
A01N 43/50 (2006.01) *A01P 13/00* (2006.01)

(21) International Application Number:
PCT/IN2022/050921

(22) International Filing Date:
17 October 2022 (17.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202121047126 18 October 2021 (18.10.2021) IN

(71) Applicant: **UPL LIMITED** [IN/IN]; UPL House, 610 B/2, Bandra Village, Off Western Express Highway, Bandra E, Mumbai 400051 (IN).

(72) Inventors: **LENZ, Giuvan**; Rod. SP 143, Km 8,5, 18580-000 Pereiras - SP (BR). **RAO, Ganesh**; UPL Limited, UPL House, 610 B/2, Bandra Village, Off Western Express Highway, Bandra E, Mumbai 400051 (IN).

(74) Agent: **ARORA, Manika**; D-17, South Extension – II, New Delhi 110049 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2023/067621 A1

(54) Title: AN AGROCHEMICAL COMBINATION

(57) Abstract: Described herein are combinations of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof with at least two herbicides. The resulting combinations may be synergistic. Also described are compositions, methods of use and kit-of-parts of the same.

AN AGROCHEMICAL COMBINATION

FIELD OF THE INVENTION

The present invention relates to an herbicidal combination for controlling weeds. More particularly, the present invention relates to synergistic herbicidal combinations, compositions, kits-in-part and method for controlling undesirable weeds.

BACKGROUND OF THE INVENTION

Weeds are undesirable plants that are detrimental to agriculture and significantly affect crop yields. Farmers use various types of herbicides to control weeds. Herbicides with varied modes of action are generally combined, which allows for broader spectrum of control and managing resistance to herbicides. However, the combinations currently known are not sufficient to control the resistant and persistent weeds.

Additionally, the combination of herbicides may not always result in the desired effect. Combinations of herbicides may result in an additive effect or an antagonistic effect. It may also result in phytotoxicity to the crops making it an undesirable combination. Consequently, herbicides need to be carefully selected so that they can be combined to offer a synergistic effect that would control weeds while having no phytotoxic effect on the crop and reduce the chances of the weeds developing resistance to a particular herbicide.

Accordingly, there is a need in the art for a synergistic herbicidal combination, composition, method and kits for protecting crops from persistent weeds, which helps in resistance management, reduces dosage of herbicides used and that has excellent residual effects.

OBJECTIVE OF THE INVENTION

It is an objective of the present invention to provide a synergistic combination for controlling weeds.

It is an objective of the present invention to provide a combination for efficient weed control, weed suppression and eradication.

It is an object of the present invention to provide a combination of highly effective herbicidal actives for selective and non-selective weed control.

It is another object of the present invention to provide a synergistic herbicidal combination to control, suppress or prevent a wide spectrum of weeds and target plants, both dicotyledonous and monocotyledonous, broad-leaved, and grassy weeds.

It is an objective of the present invention to provide a synergistic combination for controlling weeds, comprising glufosinate or L-glufosinate and at least two herbicides selected from nitrophenyl ether, imidazolinone, organophosphorous, dicarboximide, phenoxyacetic, pyridine, cyclohexene oxime, aryloxyphenoxypropionic, triazolone class of herbicides, and/or uracil class of herbicides.

It is an objective of the present invention to provide a composition for controlling weeds, comprising glufosinate or L-glufosinate and at least two herbicides selected from nitrophenyl ether, imidazolinone, organophosphorous, dicarboximide, phenoxyacetic, pyridine, cyclohexene oxime, aryloxyphenoxypropionic, triazolone class of herbicides, and/or uracil class of herbicides.

It is an objective of the present invention to provide solid or liquid formulations for controlling weeds.

It is an objective of the present invention to provide a method of controlling weeds, by application of a synergistic herbicidal combination comprising glufosinate or L-glufosinate and at least two herbicides selected from nitrophenyl ether, imidazolinone, organophosphorous, dicarboximide, phenoxyacetic, pyridine, cyclohexene oxime, aryloxyphenoxypropionic, triazolone class of herbicides, and/or uracil class of herbicides.

It is an objective of the present invention to provide a method for increasing yield in a crop by application of a synergistic combination.

It is an objective of the present invention to provide a method for improving the plant health by application of a synergistic combination at the desired locus.

It is an objective of the present invention to provide a combination or composition for use in controlling undesirable vegetation.

Additionally, it is an object of the invention to provide a method of controlling resistant varieties of weeds with a suitable herbicidal combination.

It is an object of the present invention to provide a combination of highly effective herbicidal actives for an efficient burn-down program.

It is an objective of the present invention to provide a kit-of-parts comprising a plurality of components.

SUMMARY OF THE INVENTION

In an aspect, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides; and/or
(j) uracil class of herbicides.

In another aspect, there is provided a composition for controlling the growth of undesirable vegetation, the composition comprising glufosinate, salts or esters thereof, at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;

(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides; and/or
(j) uracil class of herbicides;

and at least one agrochemically suitable excipient.

In a preferred embodiment, the glufosinate, salts or esters thereof, is L-glufosinate, salts or esters thereof.

Preferably, the second and third herbicides may be selected from within the same class of herbicides.

Preferably, the second and third herbicides may be selected from within different classes of herbicides.

In accordance with another aspect, the weight ratio of glufosinate and the at least two herbicides ranges from 1:100:100 to 100:1:1.

In accordance with another aspect, the weight ratio of glufosinate and the at least two herbicides ranges from 1:75:75 to 75:1:1.

In accordance with another aspect, there is provided a method of controlling the growth of undesirable vegetation, the method comprising treating the locus at which control is desired with a synergistic combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;

(i) triazolone class of herbicides; and/or

(j) uracil class of herbicides.

Preferably, the second and third herbicides may be selected from within the same class of herbicides.

Preferably, the second and third herbicides may be selected from within different classes of herbicides.

Preferably, the glufosinate, salts or esters thereof, is L-glufosinate, salts or esters thereof.

Preferably, the second herbicide is selected from the nitrophenyl ether class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the imidazolinone class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the organophosphorus class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the dicarboximide class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the phenoxyacetic class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the pyridine class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the cyclohexene oxime class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the aryloxyphenoxypropionic class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the triazolone class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the uracil class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class

of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

In accordance with another aspect, there is provided a method of controlling the growth of undesirable vegetation, the method comprising treating the locus with a synergistic combination of glufosinate, an herbicide selected from the imidazolinone class of herbicides, and a herbicide selected from the triazolone class of herbicides.

In accordance with another aspect, the weight ratio of glufosinate, the herbicide selected from the imidazolinone class of herbicides, and the herbicide selected from the triazolone class of herbicides ranges from 1:100:100 to 100:1:1.

In accordance with another aspect, the weight ratio of glufosinate, the herbicide selected from the imidazolinone class of herbicides, and the herbicide selected from the triazolone class of herbicides ranges from 1:75:75 to 75:1:1.

In accordance with yet another aspect, the combinations, compositions and methods of the present invention are used for controlling weeds in a range of crops.

In accordance with yet another aspect, there is provided a kit-of-parts comprising a plurality of components that may be admixed before use.

DETAILED DESCRIPTION OF THE INVENTION

Discussed below are some representative embodiments of the present invention. The invention in its broader aspects is not limited to the specific details and representative methods. Illustrative examples are described in this section in connection with the embodiments and methods provided.

For the purposes of the following detailed description, it is to be understood that the invention may assume various alternative variations and step sequences, except where expressly specified to the contrary. Moreover, other than in any operating examples, or where otherwise indicated, all numbers expressing, for example, quantities of materials/ingredients used in the specification are to be understood as being modified in all instances by the term "about" and is

meant to encompass variations of ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1% of the specified value as well as the specified value.

It is to be noted that, as used in the specification, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a composition containing "a surfactant" includes a mixture of two or more surfactants. It should also be noted that the term "'or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise. The terms "emulsifier" and "surfactant" mean essentially the same thing and may be used interchangeably. Further, the terms "composition" or "formulation" also mean essentially the same thing and may be used interchangeably.

The terms "preferred" and "preferably" refer to embodiments of the invention that may afford certain benefits, under certain circumstances.

As used herein, the terms "comprising" "including," "having," "containing," "involving," and the like are to be understood to be open-ended, i.e., to mean including but not limited to.

The expression of various quantities in terms of "%" or "% w/w" means the percentage by weight of the total solution or composition unless otherwise specified.

The terms "plants" and "vegetation" include, but are not limited to, germinant seeds, emerging seedlings, plants emerging from vegetative propagules, and established vegetation. The term 'plants' refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage and fruits. The term "weed" refers to unwanted vegetation and includes any plant which grows where it is not wanted, including pesticide resistant plants. In the broadest sense, the term "weed" refers to plants which grow in locations in which they are not desired. In other words, a "weed" is a plant in which in the context of a crop is undesirable due to competition for water, nutrients, sunlight, soil, etc. The term may also refer to crop plants which are undesirable at a location.

The terms "undesirable vegetation", "harmful plants", "unwanted plants", "weeds" and "weed species", as used herein, are synonyms.

Typically, the combinations/compositions of the present invention are applied to the targeted weed or to their locus or to the crop/plant. The term "locus" as used herein shall denote the vicinity of a desired crop in which weed control, typically selective weed control is desired.

The locus includes the vicinity of desired crop plants wherein the weed infestation has either emerged or is yet to emerge. The term crop shall include a multitude of desired crop plants or an individual crop plant growing at a locus. The said locus could be a weed, an area adjacent to the weed, soil adapted to support growth of the weed, a root of the weed and/or foliage of the weed. The 'locus' is intended to include soil, seeds, and seedlings as well as established vegetation.

In any aspect or embodiment described hereinbelow, the phrase comprising may be replaced by the phrases "consisting of" or "consisting essentially of" or "consisting substantially of". In these aspects or embodiment, the combination or composition described includes or comprises or consists of or consists essentially of or consists substantially of the specific components recited therein, to the exclusion of other herbicides or fungicides or insecticide or plant growth promoting agents or adjuvants, or excipients not specifically recited therein.

The present invention, in all its aspects, is described in detail as follows:

Glufosinate (phosphinothricin; DL-homoalanin-4-yl(methyl)phosphinic acid) is a racemic phosphinico amino acid (*Hoerlein, G. 1994; glufosinate (Phosphinothricin), a natural amino acid with unexpected herbicidal properties. Rev. of Environmental Contamination and Toxicology 138, 73 - 145*). Its ammonium salt (glufosinate-ammonium) is widely used as a non-selective herbicide and is the active ingredient of the commercial herbicide formulations Basta™, Buster™, Challenge™, Conquest™, Dash™, Final™, Finale™, Liberty™ and Ignite™. The L-isomer of glufosinate is a structural analogue of glutamate and, therefore, is a competitive inhibitor of the enzyme glutamine synthetase (GS) of bacteria and plants (*Bayer et al, 1972, Phosphinothricin and phosphinothricyl-alanyl-alanin. Helv. Chim. Acta 55, 224 - 239*; *Leason et al., 1982, Inhibition of pea leaf glutamine synthetase by methioninsulfoximine, Phosphinothricin and other glutamate analogs. J. Phytochem. 21, 855 - 857*). The D-isomer is not a GS inhibitor and is not herbicidally active.



Fig. 1. Chemical structures of D-glufosinate and L-glufosinate.

It has surprisingly been found by the present inventors that a range of weeds can be completely controlled by the combination of glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides; and/or
(j) uracil class of herbicides.

More surprisingly, it was found that this combination, between glufosinate, salts or esters thereof, and at least two herbicides provided synergistic effect in controlling a range of weeds. The degree of synergistic enhancement in efficacy of the above combination towards control of weeds was unpredictable and unexpected.

As used herein, the term "glufosinate" refers to any molecule which is a racemic phosphinico amino acid or a salt thereof. The term also includes forms and isomers of glufosinate such as glufosinate-p (L-glufosinate), D-glufosinate, and sodium, potassium or ammonium salts thereof. The term can generically refer to any form of glufosinate or its salt such as solvates, hydrates, anhydrous form, polymorph forms, pseudo polymorph forms, amorphous form or mixture thereof.

Preferably, the herbicide glufosinate, salts or esters thereof, used in any aspect or embodiment described herein may be replaced by, or used interchangeably as, its L-isomer i.e. L-glufosinate, salts or esters thereof.

As used herein, the term "L-glufosinate" refers to the L-isomer of glufosinate or a salt thereof. The L-isomer of glufosinate is a structural analogue of glutamate and, therefore, is a competitive inhibitor of the enzyme glutamine synthetase (GS) of bacteria and plants. The L-enantiomer of glufosinate acts by inhibition of glutamine synthetase thereby causing accumulation of toxic levels of ammonium ion and indirectly stopping photosynthesis. It is also known as phosphinothricin or (S)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic

acid. The term as used herein includes free acid form, salts and ester forms of L-glufosinate. The term very commonly covers derivatives such as salts and esters of L-glufosinate. The term can generically refer to any form of L-glufosinate or its salt such as free acid, solvates, hydrates, anhydrous form, polymorph forms, pseudo polymorph forms, amorphous form or mixture thereof, and sodium, potassium or ammonium salts. The term "L-glufosinate or a salt thereof" encompasses any salt of L-glufosinate, preferable sodium, potassium and ammonium salts. The salts of L-glufosinate such as monosodium salt, disodium salt, monopotassium salt, dipotassium salt, calcium salt, ammonium salt, $-NH_3(CH_3)^+$ salt, $-NH_2(CH_3)^{2+}$ salt, $-NH(CH_3)^{3+}$salt, $-NH(CH_3)_2(C_2H_4OH)^+$ salt, and $-NH_2(CH_3)(C_2H_4OH)^+$ salt are included in the definition. The agronomically acceptable salts include L-glufosinate-ammonium, L-glufosinate-sodium, and L-glufosinate-potassium. The term may also refer to an isomeric (racemic) mixture of L-glufosinate, D-glufosinate and salts thereof, wherein the content of L-glufosinate or a salt thereof in the mixture is 70% or greater, preferably 80% or greater and more preferably 90% or greater. Typically, the ratio of L-glufosinate: D-glufosinate can be in the range from about 95:5 to about 99.9:0.1.

Therefore, in an embodiment, the preferred glufosinate, salts or esters thereof herbicide is L-glufosinate, salts or esters thereof.

The term 'herbicide' as used herein denotes a compound which controls or modifies the growth of plants. The term 'herbicidally effective amount' indicates the quantity of such a compound or combination of such compounds which is capable of producing a controlling or modifying effect on the growth of plants. Controlling effects include all deviation from natural development, for example: killing, retardation, leaf burn, albinism, dwarfing etc.

In an embodiment, the present invention provides an herbicidal combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;

(i) triazolone class of herbicides; and/or

(j) uracil class of herbicides.

In an embodiment, the present invention provides an herbicidal combination for controlling the growth of undesirable vegetation, said combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;

(b) imidazolinone class of herbicides;

(c) organophosphorous class of herbicides;

(d) dicarboximide class of herbicides;

(e) phenoxyacetic class of herbicides;

(f) pyridine class of herbicides;

(g) cyclohexene oxime class of herbicides;

(h) aryloxyphenoxypropionic class of herbicides;

(i) triazolone class of herbicides; and/or

(j) uracil class of herbicides.

In a preferred embodiment, glufosinate, salts or esters thereof is L-glufosinate, salts or esters thereof.

In an embodiment, the present invention provides an herbicidal combination for controlling the growth of undesirable vegetation, said combination comprising L-glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;

(b) imidazolinone class of herbicides;

(c) organophosphorous class of herbicides;

(d) dicarboximide class of herbicides;

(e) phenoxyacetic class of herbicides;

(f) pyridine class of herbicides;

(g) cyclohexene oxime class of herbicides;

(h) aryloxyphenoxypropionic class of herbicides;

(i) triazolone class of herbicides; and/or

(j) uracil class of herbicides.

Preferably, the second and third herbicides may be selected from within the same class of herbicides.

Preferably, the second and third herbicides may be selected from within different classes of herbicides.

Preferably, the glufosinate, salts or esters thereof may be L-glufosinate, salts or esters thereof.

Preferably, the second herbicide is selected from the nitrophenyl ether class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the imidazolinone class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the organophosphorus class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the dicarboximide class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the phenoxyacetic class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone

class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the pyridine class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the cyclohexene oxime class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the aryloxyphenoxypropionic class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the triazolone class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

Preferably, the second herbicide is selected from the uracil class of herbicides, and the third herbicide is selected from the nitrophenyl ether class of herbicides; or the imidazolinone class of herbicides; or the organophosphorous class of herbicides; or dicarboximide class of herbicides; or phenoxyacetic class of herbicides; or the pyridine class of herbicides; or the

cyclohexene oxime class of herbicides; or the aryloxyphenoxypropionic class of herbicides; or the triazolone class of herbicides; or the uracil class of herbicides.

In an embodiment, said combinations of the present disclosure are tank-mix combinations.

In an embodiment, nitrophenyl ether class herbicide is selected from the group consisting of oxyfluorfen, acifluorfen, aclonifen, bifenox, chlomethoxyfen, chlornitrofen, etnipromid, fluorodifen, fluoroglycofen, fluoronitrofen, fomesafen, fucaomi, furyloxyfen, halosafen, lactofen, nitrofen, nitrofluorfen, and combinations thereof.

In a preferred embodiment, the nitrophenyl ether class herbicide is oxyfluorfen.

In a preferred embodiment, the nitrophenyl ether class herbicide is acifluorfen.

In a preferred embodiment, the nitrophenyl ether class herbicide is fomesafen.

In a preferred embodiment, the nitrophenyl ether class herbicide is aclonifen.

In an embodiment, the imidazolinone class herbicide is selected from the group consisting of imazethapyr, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin and combinations thereof.

In a preferred embodiment, the imidazolinone class herbicide is imazethapyr.

In a preferred embodiment, the imidazolinone class herbicide is imazamox.

In a preferred embodiment, the imidazolinone class herbicide is imazapyr.

In a preferred embodiment, the imidazolinone class herbicide is imazapic.

In an embodiment, the organophosphorous class of herbicide is selected from the group consisting of glyphosate, amiprofos-methyl, amiprophos, anilofos, bensulide, bilanafos, butamifos, clacyfos, 2,4-DEP (2,4-Dichlorophenoxyethylphosphite), DMPA (O-(2,4-Dichlorophenyl) O-Methyl Isopropylphosphoramidothioate), EBEP (ethyl bis(2-ethylhexyl)phosphinate), fosamine, huangcaoling, piperophos, shuangjiaancaolin and combinations thereof.

In a preferred embodiment, the organophosphorous class herbicide is glyphosate.

In an embodiment, the dicarboximide class herbicide is selected from the group consisting of flumioxazin, cinidon-ethyl, flumezin, flumiclorac, flumipropyn, and combinations thereof.

In a preferred embodiment, the dicarboximide class herbicide is flumioxazin.

In an embodiment, the phenoxyacetic class herbicide is selected from the group consisting of clacyfos, 2,4-D, 4-CPA (p-Chlorophenoxyacetic acid), 3,4-DA, MCPA (2-METHYL-4-CHLOROPHENOXYACETIC ACID), MCPA-thioethyl, 2,4,5-T, and combinations thereof.

In a preferred embodiment, the phenoxyacetic class herbicide is 2,4-D.

In a preferred embodiment, the phenoxyacetic class herbicide is MCPA.

In an embodiment, pyridine class herbicide is selected from the group consisting of triclopyr, aminopyralid, cliodinate, clopyralid, diflufenican, dithiopyr, florpyrauxifen, flufenican, fluroxypyr, halauxifen, haloxydine, picloram, picolinafen, pyriclor, pyroxsulam, thiazopyr, xyloxadine, and combinations thereof.

In a preferred embodiment, the pyridine class herbicide is triclopyr.

In a preferred embodiment, the pyridine class herbicide is diflufenican.

In a preferred embodiment, the pyridine class herbicide is flufenican.

In a preferred embodiment, the pyridine class herbicide is fluroxypyr.

In a preferred embodiment, the pyridine class herbicide is picloram.

In a preferred embodiment, the pyridine class herbicide is pyroxsulam.

In an embodiment, the cyclohexene oxime class herbicide is selected from the group consisting of clethodim, alloxydim, butroxydim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim, and combinations thereof.

In a preferred embodiment, the cyclohexene oxime class herbicide is clethodim.

In an embodiment, the aryloxyphenoxypropionic class herbicide is selected from the group consisting of haloxyfop, chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop-P, isoxapyrifop, kuicaoxi, metamifop, propaquizafop, quizalofop, quizalofop-P, quizalofop-ethyl, quizalofo-P-tefuryl, trifop, and combinations thereof.

In a preferred embodiment, the aryloxyphenoxypropionic class herbicide is haloxyfop or haloxyfop-P.

In a preferred embodiment, the aryloxyphenoxypropionic class herbicide is clodinafop.

In a preferred embodiment, the aryloxyphenoxypropionic class herbicide is fenoxaprop or fenoxaprop-P.

In a preferred embodiment, the aryloxyphenoxypropionic class herbicide is quizalofop or quizalofop-P.

In a preferred embodiment, the aryloxyphenoxypropionic class herbicide is quizalofop-ethyl or quizalofop-P-tefuryl.

In an embodiment, the triazolone class herbicide is selected from the group consisting of carfentrazone, amicarbazone, bencarbazone, flucarbazone, ipfencarbazone, propoxycarbazone, sulfentrazone, thiencarbazone and combinations thereof.

In a preferred embodiment, the triazolone class herbicide is carfentrazone.

In a preferred embodiment, the triazolone class herbicide is amicarbazone.

In a preferred embodiment, the triazolone class herbicide is flucarbazone.

In a preferred embodiment, the triazolone class herbicide is ipfencarbazone.

In a preferred embodiment, the triazolone class herbicide is sulfentrazone.

In an embodiment, the uracil class herbicide is selected from the group consisting of bromacil, isocil, lenacil, terbacil, benzfendizone, butafenacil, epyrifenacil, flupropacil, saflufenacil, tiafenacil, and combinations thereof.

In a preferred embodiment, the uracil class herbicide is saflufenacil.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising glufosinate, salts or esters thereof and at least two herbicides, wherein the weight ratio of glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:100:100 to 100:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising L-glufosinate, salts or esters thereof and at least two herbicides, wherein the weight ratio of L-glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:100:100 to 100:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising glufosinate, salts or esters thereof and at

least two herbicides, wherein the weight ratio of glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:75:75 to 75:1:1.

In an embodiment, preferably, the weight ratio of glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:50:50 to 50:1:1.

More preferably, the weight ratio between glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:25:25 to 25:1:1, more preferably 1:10:10 to 10:1:1.

In a preferred embodiment, the weight ratio between glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:5:5 to 5:1:1, even more preferably 1:2:2 to 2:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising L-glufosinate, salts or esters thereof and at least two herbicides, wherein the weight ratio of L-glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:75:75 to 75:1:1.

In an embodiment, preferably, the weight ratio of L-glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:50:50 to 50:1:1.

More preferably, the weight ratio between L-glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:25:25 to 25:1:1, more preferably 1:10:10 to 10:1:1.

In a preferred embodiment, the weight ratio between L-glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:5:5 to 5:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising glufosinate, salts or esters thereof and at least two herbicides, wherein the weight ratio of glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:100 to 100:1.

Preferably, the weight ratio of glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In a yet another preferred embodiment, the weight ratio of glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:10 to 10:1, more preferably 1:5 to 5:1 and even more preferably 1:2 to 2:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation, said combination comprising L-glufosinate, salts or esters thereof and

at least two herbicides, wherein the weight ratio of L-glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:100 to 100:1.

Preferably, the weight ratio of L-glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In a yet another preferred embodiment, the weight ratio of L-glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:10 to 10:1, more preferably 1:5 to 5:1.

According to an embodiment, the combinations of the present invention are illustrated below in Table 1.

Table 1: Exemplary combinations of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof with at least two herbicides

Herbicide 1	**Herbicide 2**	**Herbicide 3**	**Ratio of Herbicide 1:Herbicide 2 in combination and Herbicide 1:Herbicide 3 in combination**	**Ratio of Herbicide 2:Herbicide 3 in combination**
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	nitrophenyl ether herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	nitrophenyl ether herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	nitrophenyl ether herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	nitrophenyl ether herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	imidazolinone herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	imidazolinone herbicide	organophosphoro us herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	imidazolinone herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	imidazolinone herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	organophosphorous herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof		different from component 1	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	organophosphorous herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	organophosphorous herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	dicarboximide herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	dicarboximide herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	dicarboximide herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	dicarboximide herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	phenoxyacetic herbicide	organophosphoro us herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	phenoxyacetic herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	phenoxyacetic herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	phenoxyacetic herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	pyridine herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	pyridine herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	pyridine herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	pyridine herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	cyclohexene oxime herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	cyclohexene oxime herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	cyclohexene oxime herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereofor L-glufosinate, salts or esters thereof	cyclohexene oxime herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	aryloxyphenoxypropionic herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	aryloxyphenoxypropionic herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof		different from component 1	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	aryloxyphenoxypropionic herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	triazolone herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	triazolone herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	triazolone herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	triazolone herbicide	uracil herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	nitrophenyl ether herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	imidazolinone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	uracil herbicide	organophosphorous herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	dicarboximide herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	phenoxyacetic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	pyridine herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	cyclohexene oxime herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate,	uracil herbicide	aryloxyphenoxypropionic herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to

salts or esters thereof			50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	triazolone herbicide	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	uracil herbicide	uracil herbicide different from component 1	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Preferably, the following exemplary combinations of the invention as illustrated in Table 2 were synergistic:

Table 2

Herbicide 1	**Herbicide 2**	**Herbicide 3**	**Ratio of Herbicide 1:Herbicide 2 in combination and Herbicide 1:Herbicide 3 in combination**	**Ratio of Herbicide 2:Herbicide 3 in combination**
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Oxyfluorfen	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Oxyfluorfen	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Oxyfluorfen	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Oxyfluorfen	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Acifluorfen	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Acifluorfen	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Acifluorfen	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Acifluorfen	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Fomesafen	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Fomesafen	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Fomesafen	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fomesafen	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Aclonifen	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Aclonifen	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Aclonifen	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Aclonifen	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Imazethapyr	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Imazethapyr	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Imazethapyr	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazethapyr	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Imazamox	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Imazamox	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Imazamox	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazamox	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Imazapyr	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Imazapic	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Glyphosate	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Imazapyr	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Imazapyr	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Imazapyr	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Imazapyr	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Glyphosate	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Glyphosate	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Glyphosate	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Flumioxazin	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Flumioxazin	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Flumioxazin	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Flumioxazin	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flumioxazin	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	2,4-D	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	2,4-D	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	2,4-D	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	MCPA	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	MCPA	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	MCPA	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	MCPA	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	MCPA	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Diflufenican	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Diflufenican	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Diflufenican	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Diflufenican	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Flufenican	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Flufenican	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Flufenican	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flufenican	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Fluroxypyr	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Fluroxypyr	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Fluroxypyr	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Fluroxypyr	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Picloram	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Picloram	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Picloram	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Picloram	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Pyroxsulam	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Pyroxsulam	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Picloram	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Pyroxsulam	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Pyroxsulam	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Clethodim	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Clethodim	Pyroxsulam	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Clethodim	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clethodim	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Haloxyfop	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Haloxyfop	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Clodinafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Haloxyfop	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Haloxyfop	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Clodinafop	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Clodinafop	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Clodinafop	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Clodinafop	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Quizalafop	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Quizalafop	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Quizalafop	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Carfentrazone	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Carfentrazone	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Quizalafop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Carfentrazone	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Carfentrazone	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Amicarbazone	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Amicarbazone	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Amicarbazone	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Amicarbazone	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Flucarbazone	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Flucarbazone	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Flucarbazone	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Sulfentrazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Sulfentrazone	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Sulfentrazone	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Sulfentrazone	Saflufenacil	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Acifluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Fomesafen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Aclonifen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Saflufenacil	Imazamox	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Imazethapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Imazapyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Oxyfluorfen	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Flumioxazin	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	2,4-D	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	MCPA	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Diflufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Flufenican	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Fluroxypyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Triclopyr	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate,	Saflufenacil	Clethodim	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more

salts or esters thereof			preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Haloxyfop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Fenoxaprop	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Carfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Amicarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Ipfencarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-	Saflufenacil	Flucarbazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1,

glufosinate, salts or esters thereof			even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.
Glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof	Saflufenacil	Sulfentrazone	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.	100:1 to 1:100, preferably 1:75 to 75:1, more preferably 1:50 to 50:1, even more preferably 1:25 to 25:1, even more preferably 1:10 to 10:1 and most preferably 1:5 to 5:1.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein glufosinate, salts or esters thereof is present in an amount in the range of 100 to 400 g ai/L, preferably 180 to 380 g ai/L, more preferably 250 to 350 g ai/L. In a preferred embodiment, the formulation comprises 280 g ai/L of glufosinate, salts or esters thereof.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from nitrophenyl ether class of herbicides, and wherein the nitrophenyl ether class of herbicides is present in the formulation in an amount in the range of 100 to 400 g ai/L, preferably 140 to 340 g ai/L, more preferably 200 to 250 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the formulation in an amount in the range of 10 to 250 g ai/L, preferably 50 -200 g ai/L, more preferably 75 -125 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the formulation in an amount in the range of 100 to 1000 g ai/L, preferably 100 - 800 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from organophosphorous class of herbicides, and wherein the organophosphorous class of herbicides is present in the formulation in an amount in the range of 200 to 1000 g ai/L, preferably 400 to 800 g ai/L, more preferably 500 - 700 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from dicarboximide class of herbicides, and wherein the dicarboximide class of herbicides is present in the formulation in an amount in the range of 200 – 800 g ai/L, preferably 300 to 700 g ai/L, more preferably 400-600 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is present in the formulation in an amount in the range of 200 to 1200 g ai/L, preferably 400 - 1000 g ai/L, more preferably 450 – 850 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is present in the formulation in an amount in the range of 400 to 1200 g ai/L, preferably 600 - 1000 g ai/L, more preferably 750 – 850 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the formulation in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 400 to 750 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the formulation in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 500 to 750 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from cyclohexene oxime class of herbicides, and wherein the cyclohexene oxime class of herbicides is present in the formulation in an amount in the range of 100 – 400 g ai/L, preferably 150 to 350 g ai/L, preferably 200-300 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from aryloxyphenoxypropionic class of herbicides, and wherein the aryloxyphenoxypropionic class of herbicides is present in the formulation in an amount in the range of 1 to 250 g ai/L, preferably 10 – 200 g ai/L and more preferably 50 – 150 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from triazolone class of herbicides, and wherein the triazolone class of herbicides is present in the formulation in an amount in the range of 100 – 800 g ai/L, preferably 200 to 600 g ai/L, more preferably 300 to 500 g ai/L.

In an embodiment, the combinations of the present invention comprise of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from uracil class of herbicides, and wherein the uracil class of herbicides is present in the formulation in an amount in the range of 1-1000 g ai/L, preferably 50 to 800 g ai/L.

More surprisingly, it was found that this combination of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, an herbicide selected from the imidazolinone class of herbicides, and an herbicide selected from the triazolone class of herbicides, acted in a synergistic manner in controlling a range of weeds. The degree of synergistic enhancement in efficacy of the above combination towards control a range of weeds was unpredictable and unexpected.

Therefore, in an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof; a herbicide selected from the imidazolinone class of herbicides, and a herbicide selected from the triazolone class of herbicides.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the herbicide selected from the imidazolinone class of herbicides is imazethapyr, and wherein the herbicide selected from the triazolone class of herbicides is carfentrazone.

In another embodiment, the present invention provides a combination of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazethapyr and carfentrazone, for controlling the growth of undesirable vegetation and weeds, wherein the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazethapyr, and carfentrazone ranges from 1:100:100 to 100:1:1. Preferably, the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazethapyr, and carfentrazone ranges from 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1, even more preferably from 1:25:25 to 25:1:1.

In an embodiment, the weight ratio of glufosinate, salts or esters thereof, imazethapyr, and carfentrazone ranges from 1:10:10 to 10:1:1, preferably from 1:5:5 to 5:1:1, more preferably from 1:2:2 to 2:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof; an herbicide selected from the phenoxyacetic class of herbicides, and an herbicide selected from the uracil class of herbicides.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the herbicide selected from the phenoxyacetic class of herbicides is 2,4-D, and wherein the herbicide selected from the uracil class of herbicides is saflufenacil.

In another embodiment, the present invention provides a combination of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, 2,4-D and saflufenacil, for controlling the growth of undesirable vegetation and weeds, wherein the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, 2,4D, and saflufenacil ranges from 1:100:100 to 100:1:1. Preferably, the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, 2,4-D, and saflufenacil ranges from 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1, even more preferably from 1:25:25 to 25:1:1.

In an embodiment, the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, 2,4D, and saflufenacil ranges from 1:10:10 to 10:1:1, preferably from 1:5:5 to 5:1:1.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof; an herbicide selected from the pyridine class of herbicides, and an herbicide selected from the uracil class of herbicides.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the herbicide selected from the pyridine class of herbicides is triclopyr, and wherein the herbicide selected from the uracil class of herbicides is saflufenacil.

In another embodiment, the present invention provides a combination of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, triclopyr and saflufenacil, for controlling the growth of undesirable vegetation and weeds, wherein the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, triclopyr, and saflufenacil ranges from 1:100:100 to 100:1:1. Preferably, the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, triclopyr, and saflufenacil ranges from 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1, even more preferably from 1:25:25 to 25:1:1.

In an embodiment, the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, triclopyr, and saflufenacil ranges from 1:10:10 to 10:1:1, preferably from 1:5:5 to 5:1:1.

in an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof; and two herbicides selected from the imidazolinone class of herbicides.

In an embodiment, the present invention provides a combination for controlling the growth of undesirable vegetation and weeds, wherein the combination comprises glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and at least two herbicides of imidazolinones class of herbicides, wherein the two herbicides selected from the imidazolinone class of herbicides are imazapic and imazapyr.

In another embodiment, the present invention provides a combination of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazapic and imazapyr, for controlling the growth of undesirable vegetation and weeds, wherein the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazapic, and imazapyr ranges from 1:100:100 to 100:1:1. Preferably, the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, imazapic, and imazapyr ranges from 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1, even more preferably from 1:25:25 to 25:1:1.

In an embodiment, the weight ratio of glufosinate, salts or esters thereof, imazapic, and imazapyr ranges from 1:10:10 to 10:1:1, preferably from 1:5:5 to 5:1:1.

In an embodiment, the present invention provides a composition comprising the combinations of the present invention along with at least one agrochemically suitable excipient.

In an embodiment, the present invention provides an herbicidal composition comprising glufosinate, salts or esters thereof, at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides;
(j) uracil class of herbicides,

and at least one agrochemically suitable excipient.

In an embodiment, the present invention provides an herbicidal composition comprising L-glufosinate, salts or esters thereof, at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;

(f) pyridine class of herbicides;

(g) cyclohexene oxime class of herbicides;

(h) aryloxyphenoxypropionic class of herbicides;

(i) triazolone class of herbicides;

(j) uracil class of herbicides,

and at least one agrochemically suitable excipient.

In an embodiment, the said composition is a tank-mix composition.

In an embodiment, the said composition comprises glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides in a synergistic combination, wherein the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and the at least two herbicides is 1:100:100 to 100:1:1, preferably 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1 and even more preferably 1:25:25 to 25:1:1.

In an embodiment, the said composition comprises glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides in a synergistic combination, wherein the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and one of the two herbicides is 1:100 to 100:1, preferably 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In an embodiment, the said composition comprises glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides in a synergistic combination, wherein the weight ratio of the two herbicides is 1:100 to 100:1, preferably 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In an embodiment, the compositions of the present invention additionally comprise one or more agrochemically suitable excipients such as adjuvants, additives, or carriers along with other ingredients such as surfactants.

The agrochemically suitable excipient may be any one or a combination of adjuvants, co-solvents, surfactants, colorants, dispersants, diluents, emulsifiers, fillers, thickening agents, antifreeze agents, freezing agents, biocides, anti-foaming agents, stabilizers, wetting agents or a mixture thereof which may be optionally added to the compositions of the present invention.

The surfactants may be selected from non-ionic, anionic or cationic surfactants.

Examples of nonionic surfactants include polyarylphenol polyethoxyethers, polyalkylphenol polyethoxy ethers, polyglycol ether derivatives of saturated fatty acids, polyglycol ether derivatives of unsaturated fatty acids, polyglycol ether derivatives of aliphatic alcohols, polyglycol ether derivatives of cycloaliphatic alcohols, fatty acid esters of polyoxyethylene sorbitan, alkoxylated vegetable oils, alkoxylated acetylenic diols, polyalkoxylated alkylphenols, fatty acid alkoxylates, sorbitan alkoxylates, sorbitol esters, C8-C22 alkyl or alkenyl polyglycosides, polyalkoxy styrylaryl ethers, alkylamine oxides, block copolymer ethers, polyalkoxylated fatty glyceride, polyalkylene glycol ethers, linear aliphatic or aromatic polyesters, organo silicones, polyaryl phenols, sorbitol ester alkoxylates, polyalkylene oxide block copolymers, acrylic copolymers and mono- and diesters of ethylene glycol and mixtures thereof.

Examples of anionic surfactants include alcohol sulfates, alcohol ether sulfates, alkylaryl ether sulfates, alkylaryl sulfonates such as alkylbenzene sulfonates and alkylnaphthalene sulfonates and salts thereof, alkyl sulfonates, mono- or di-phosphate esters of polyalkoxylated alkyl alcohols or alkylphenols , mono- or di-sulfosuccinate esters of C12-C15 alkanols or polyalkoxylated C12-C15 alkanols, alcohol ether carboxylates, phenolic ether carboxylates, polybasic acid esters of ethoxylated polyoxyalkylene glycols consisting of oxybutylene or the residue of tetrahydrofuran, sulfoalkylamides and salts thereof such as N-methyl-N-oleoyltaurate Na salt, polyoxyalkylene alkylphenol carboxylates, polyoxyalkylene alcohol carboxylates alkyl polyglycoside/alkenyl succinic anhydride condensation products, alkyl ester sulfates, napthalene sulfonates, naphthalene formaldehyde condensates, alkyl sulfonamides, sulfonated aliphatic polyesters, sulfate esters of styrylphenyl alkoxylates, and sulfonate esters of styrylphenyl alkoxylates and their corresponding sodium, potassium, calcium, magnesium, zinc, ammonium, alkylammonium, diethanolammonium, or triethanolammonium salts, salts of ligninsulfonic acid such as the sodium, potassium, magnesium, calcium or ammonium salt, polyarylphenol polyalkoxyether sulfates and polyarylphenol polyalkoxyether phosphates, and sulfated alkyl phenol ethoxylates and phosphated alkyl phenol ethoxylates.

Cationic surfactants include alkanol amides of C8-C18 fatty acids and C8-C18 fatty amine polyalkoxylates, C10-C18 alkyldimethylbenzylammonium chlorides, coconut alkyldimethylaminoacetic acids, and phosphate esters of C8-C18 fatty amine polyalkoxylates.

Emulsifiers which can be advantageously employed herein can be readily determined by those skilled in the art and include various non-ionic, anionic, cationic and amphoteric emulsifiers,

or a blend of two or more emulsifiers. Examples of nonionic emulsifiers useful in preparing the emulsifiable concentrates include the polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids with ethylene oxide, propylene oxides such as the ethoxylated alkyl phenols and carboxylic esters solubilized with the polyol or polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include the oil-soluble salts (e.g., calcium) of alkylaryl sulfonic acids, oil-soluble salts or sulfated polyglycol ethers and appropriate salts of phosphated polyglycol ether.

In an embodiment, colorants may be selected from iron oxide, titanium oxide and Prussian Blue, and organic dyestuffs, such as alizarin dyestuffs, azo dyestuffs or metal phthalocyanine dyestuffs, and trace elements, such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

Another embodiment involves addition of a thickening agent or binder which may be selected from but not limited to molasses, granulated sugar, alginates, karaya gum, jaguar gum, tragacanth gum, polysaccharide gum, mucilage, xanthan gum or combination thereof. In another embodiment, the binder may be selected from silicates such as magnesium aluminium silicate, polyvinyl acetates, polyvinyl acetate copolymers, polyvinyl alcohols, polyvinyl alcohol copolymers, celluloses, including ethylcelluloses and methylcelluloses, hydroxymethyl celluloses, hydroxypropylcelluloses, hydroxymethylpropyl-celluloses, polyvinylpyrolidones, dextrins, malto-dextrins, polysaccharides, fats, oils, proteins, gum arabics, shellacs, vinylidene chloride, vinylidene chloride copolymers, calcium lignosulfonates, acrylic copolymers, starches, polyvinylacrylates, zeins, gelatin, carboxymethylcellulose, chitosan, polyethylene oxide, acrylimide polymers and copolymers, polyhydroxyethyl acrylate, methylacrylimide monomers, alginate, ethylcellulose, polychloroprene and syrups or mixtures thereof; polymers and copolymers of vinyl acetate, methyl cellulose, vinylidene chloride, acrylic, cellulose, polyvinylpyrrolidone and polysaccharide; polymers and copolymers of vinylidene chloride and vinyl acetate-ethylene copolymers; combinations of polyvinyl alcohol and sucrose; plasticizers such as glycerol, propylene glycol and polyglycols.

In another embodiment, antifreeze agent(s) added to the composition may be alcohols selected from the group comprising of but not limited to ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 1,4-pentanediol, 3-methyl-

1,5-pentanediol, 2,3-dimethyl-2,3-butanediol, trimethylol propane, mannitol, sorbitol, glycerol, pentaerythritol, 1,4-cyclohexanedimethanol, xylenol, bisphenols such as bisphenol A or the like. In addition, ether alcohols such as diethylene glycol, triethylene glycol, tetraethylene glycol, polyoxyethylene or polyoxypropylene glycols of molecular weight up to about 4000, diethylene glycol monomethylether, diethylene glycol monoethylether, triethylene glycol monomethylether, butoxyethanol, butylene glycol monobutylether, dipentaerythritol, tripentaerythritol, tetrapentaerythritol, diglycerol, triglycerol, tetraglycerol, pentaglycerol, hexaglycerol, heptaglycerol or octaglycerol may also be used.

According to an embodiment, biocides may be selected from benzothiazoles, 1,2-benzisothiazolin-3-one, sodium dichloro-s-triazinetrione, sodium benzoate, potassium sorbate, 1,2-phenyl-isothiazolin-3-one, inter chloroxylenol paraoxybenzoate butyl.

According to an embodiment, antifoaming agent may be selected from Polydimethoxysiloxane, polydimethylsiloxane, Alkyl poly acrylates, Castor Oil, Fatty Acids, Fatty Acids Esters, Fatty Acids Sulfate, Fatty Alcohol, Fatty Alcohol Esters, Fatty Alcohol Sulfate, Foot Olive Oil, Mono & Di Glyceride, Paraffin Oil, Paraffin Wax, Poly Propylene Glycol, Silicones Oil, Vegetable & Animal Fats, Vegetable & Animal Fats Sulfate, Vegetable & Animal Oil, Vegetable & Animal Oil Sulfate, Vegetable & Animal Wax, Vegetable & Animal Wax Sulfate, agents based on silicon or magnesium stearate.

Representative organic liquids which can be employed in preparing the emulsifiable concentrates of the present invention are the aromatic liquids such as xylene, propyl benzene fractions, or mixed naphthalene fractions, mineral oils, substituted aromatic organic liquids such as dioctyl phthalate, kerosene, dialkyl amides of various fatty acids, particularly the dimethyl amides of fatty glycols and glycol derivatives such as the n-butyl ether, ethyl ether or methyl ether of diethylene glycol, and the methyl ether of triethylene glycol. Mixtures of two or more organic liquids are also often suitably employed in the preparation of the emulsifiable concentrate. The formulations can also contain other compatible additives, for example, plant growth regulators and other biologically active compounds used in agriculture.

The additives to be used for the formulation include, for example, a solid carrier such as kaolinite, sericite, diatomaceous earth, slaked lime, calcium carbonate, talc, white carbon, kaoline, bentonite, clay, sodium carbonate, sodium bicarbonate, mirabilite, zeolite or starch; a solvent such as water, toluene, xylene, solvent naphtha, dioxane, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or an alcohol; an anionic

surfactant such as a salt of fatty acid, a benzoate, a polycarboxylate, a salt of alkylsulfuric acid ester, an alkyl sulfate, an alkylaryl sulfate, an alkyl diglycol ether sulfate, a salt of alcohol sulfuric acid ester, an alkyl sulfonate, an alkylaryl sulfonate, an aryl sulfonate, a lignin sulfonate, an alkyldiphenylether disulfonate, a polystyrene sulfonate, a salt of alkylphosphoric acid ester, an alkylaryl phosphate, a styrylaryl phosphate, a salt of polyoxyethylene alkyl ether sulfuric acid ester, a polyoxyethylene alkylaryl ether sulfate, a salt of polyoxyethylene alkylaryl ether sulfuric acid ester, a polyoxyethylene alkyl ether phosphate, a salt of polyoxyethylene alkylaryl phosphoric acid ester, a salt of polyoxyethylene aryl ether phosphoric acid ester, a naphthalene sulfonic acid condensed with formaldehyde or a salt of alkylnaphthalene sulfonic acid condensed with formaldehyde; a nonionic surfactant such as a sorbitan fatty acid ester, a glycerin fatty acid ester, a fatty acid polyglyceride, a fatty acid alcohol polyglycol ether, acetylene glycol, acetylene alcohol, an oxyalkylene block polymer, a polyoxyethylene alkyl ether, a polyoxyethylene alkylaryl ether, a polyoxyethylene styrylaryl ether, a polyoxyethylene glycol alkyl ether, polyethylene glycol, a polyoxyethylene fatty acid ester, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene glycerin fatty acid ester, a polyoxyethylene hydrogenated castor oil or a polyoxypropylene fatty acid ester; and a vegetable oil or mineral oil such as olive oil, kapok oil, castor oil, palm oil, camellia oil, coconut oil, sesame oil, corn oil, rice bran oil, peanut oil, cottonseed oil, soybean oil, rapeseed oil, linseed oil, tung oil or liquid paraffins. These additives may suitably be selected for use alone or in combination as a mixture of two or more of them, so long as the object of the present invention is met. Further, additives other than the above-mentioned may be suitably selected for use among those known in this field. For example, various additives commonly used, such as a filler, a thickener, an anti-settling agent, an anti-freezing agent, a dispersion stabilizer, a safener, an anti-mold agent, a bubble agent, a disintegrator and a binder, may be used.

The agrochemical formulation may also comprise one or more antioxidants. Preferably, the agrochemical formulation comprises an antioxidants. Antioxidants are, for example, amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazole and imidazole derivatives (e.g. urocanic acid), peptides, such as, for example, D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and further thio compounds (e.g. thioglycerol, thiosorbitol, thioglycolic acid, thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl, lauryl, palmitoyl,

oleyl, γ-linoleyl, cholesteryl and glyceryl esters thereof), and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), and sulfoximine compounds (e.g. buthionine sulfoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximine) in very low tolerated doses (e.g. pmol/kg to pmol/kg), also metal chelating agents (e.g. α-hydroxy fatty acids, EDTA, EGTA, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acids, bile acid, bile extracts, gallic esters (e.g. propyl, octyl and dodecyl gallate), flavonoids, catechins, bilirubin, biliverdin and derivatives thereof, unsaturated fatty acids and derivatives thereof (e.g. γ-linolenic acid, linoleic acid, arachidonic acid, oleic acid), folic acid and derivatives thereof, hydroquinone and derivatives thereof (e.g. arbutin), ubiquinone and ubiquinol, and derivatives thereof, vitamin C and derivatives thereof (e.g. ascorbyl palmitate, stearate, dipalmitate, acetate, Mg ascorbyl phosphates, sodium and magnesium ascorbate, disodium ascorbyl phosphate and sulfate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate), isoascorbic acid and derivatives thereof, tocopherols and derivatives thereof (e.g. tocopheryl acetate, linoleate, oleate and succinate, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50, tocophersolan), vitamin A and derivatives (e.g. vitamin A palmitate), the coniferyl benzoate of benzoin resin, rutin, rutinic acid and derivatives thereof, disodium rutinyl disulfate, cinnamic acid and derivatives thereof (e.g. ferulic acid, ethyl ferulate, caffeeic acid), kojic acid, chitosan glycolate and salicylate, butylhydroxytoluene, butylhydroxyanisol, nordihydroguaiacic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, selenium and selenium derivatives (e.g. selenomethionine), stilbenes and stilbene derivatives (e.g. stilbene oxide, trans-stilbene oxide). According to the invention, suitable derivatives (salts, esters, sugars, nucleotides, nucleosides, peptides and lipids) and mixtures of these specified active ingredients or plant extracts (e.g. teatree oil, rosemary extract and rosemarinic acid) which comprise these antioxidants can be used. In general, mixtures of the aforementioned antioxidants are possible.

According to an embodiment, examples of suitable solvents are water, aromatic solvents (for example Solvesso products, xylene), paraffins (for example mineral oil fractions such as kerosene or diesel oil), coal tar oils and oils of vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, for example toluene, xylene, paraffin, tetrahydronaphthalene, alkylated naphthalenes or their derivatives, alcohols (for example methanol, butanol, pentanol, benzyl alcohol, cyclohexanol), ketones (for example cyclohexanone, gamma-butyrolactone),

pyrrolidones (NMP, NEP, NOP), acetates (glycol diacetate), glycols, fatty acid dimethylamides, fatty acids and fatty acid esters, isophorone and dimethylsulfoxide. In principle, solvent mixtures may also be used.

According to an embodiment, suitable surfactants are alkali metal, alkaline earth metal and ammonium salts of lignosulfonic acid, naphthalenesulfonates, phenolsulfonic acid, dibutylnaphthalenesulfonic acid, alkylarylsulfonates, alkyl sulfates, alkylsulfonates, fatty alcohol sulfates, fatty acids and sulfated fatty alcohol glycol ethers, furthermore condensates of sulfonated naphthalene and naphthalene derivatives with formaldehyde, condensates of naphthalene or of naphthalenesulfonic acid with phenol and formaldehyde, polyoxyethylene octylphenol ethers, ethoxylated isooctylphenol, octylphenol, nonylphenol, alkylphenol polyglycol ethers, tributylphenyl polyglycol ethers, tristearylphenyl polyglycol ethers, alkylaryl polyether alcohols, alcohol and fatty alcohol/ethylene oxide condensates, ethoxylated castor oil, polyoxyethylene alkyl ethers, ethoxylated polyoxypropylene, lauryl alcohol polyglycol ether acetal, sorbitol esters, lignosulfite waste liquors and methylcellulose.

According to an embodiment, examples of suitable carriers are mineral earths such as silica gels, silicates, talc, kaolin, attaclay, attapulgite, limestone, lime, chalk, bole, loess, clay, dolomite, diatomaceous earth, calcium sulfate, magnesium sulfate, magnesium oxide, ground synthetic materials, fertilizers, such as, for example, ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas, and products of vegetable origin, such as cereal meal, tree bark meal, wood meal and nutshell meal, cellulose powders, polyvinylpyrrolidone and other solid carriers.).

Suitable preservatives are for example 1,2-benzisothiazolin-3-one and/or 2-Methyl-2H-isothiazol-3-one or sodium benzoate or benzoic acid.

In an embodiment, the composition may be in any agriculturally suitable form for storage and application to the ground. The compositions of the present invention may typically be produced by mixing the actives in the composition with an inert carrier, and adding surfactants and other adjuvants and carriers as needed and formulated into solid, or liquid formulations, including but not limited to powders, wettable powders, pellets, tablets, granules, dusts, dry flowables, water-dispersible granules, microcapsules, soluble (liquid) concentrates, suspension concentrates, oil in water emulsion, water in oil emulsion, emulsifiable concentrates, capsule suspensions, ZC formulations, oil dispersions or other known formulation types.

The terms "g ai/L" as used herein denotes the concentration of the respective active ingredient in "grams" present "per litre" of the composition.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein glufosinate, salts or esters thereof is present in an amount in the range of 100 to 400 g ai/L, preferably 180 to 380 g ai/L, more preferably 250 to 350 g ai/L. In a preferred embodiment, the formulation comprises 280 g ai/L of glufosinate, salts or esters thereof.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from nitrophenyl ether class of herbicides, and wherein the nitrophenyl ether class of herbicides is present in the formulation in an amount in the range of 100 to 400 g ai/L, preferably 140 to 340 g ai/L, more preferably 200 to 250 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the formulation in an amount in the range of 10 to 250 g ai/L, preferably 50 -200 g ai/L, more preferably 75 -125 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the formulation in an amount in the range of 100 to 1000 g ai/L, preferably 100 - 800 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from organophosphorous class of herbicides, and wherein the organophosphorous class of herbicides is present in the formulation in an amount in the range of 200 to 1000 g ai/L, preferably 400 to 800 g ai/L, more preferably 500 - 700 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from dicarboximide class of herbicides, and wherein the dicarboximide class of herbicides is present in the formulation in an amount in the range of 200 – 800 g ai/L, preferably 300 to 700 g ai/L, more preferably 400-600 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is present in the formulation in an amount in the range of 200 to 1200 g ai/L, preferably 400 - 1000 g ai/L, more preferably 450 – 850 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is present in the formulation in an amount in the range of 400 to 1200 g ai/L, preferably 600 - 1000 g ai/L, more preferably 750 – 850 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the formulation in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 400 to 750 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the formulation in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 500 to 750 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from cyclohexene oxime class of herbicides, and wherein the cyclohexene oxime class of herbicides is present in the formulation in an amount in the range of 100 – 400 g ai/L, preferably 150 to 350 g ai/L, preferably 200-300 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from aryloxyphenoxypropionic class of herbicides, and wherein the aryloxyphenoxypropionic class of herbicides is present in the formulation in an amount in the range of 1 to 250 g ai/L, preferably 10 – 200 g ai/L and more preferably 50 – 150 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from triazolone class of herbicides, and wherein the triazolone class of herbicides is present in the formulation in an amount in the range of 100 – 800 g ai/L, preferably 200 to 600 g ai/L, more preferably 300 to 500 g ai/L.

In an embodiment, the liquid formulations comprise of glufosinate, salts or esters thereof, and at least two herbicides, wherein the at least one herbicide is selected from uracil class of herbicides, and wherein the uracil class of herbicides is present in the formulation in an amount in the range of 1-1000 g ai/L, preferably 50 to 800 g ai/L.

The composition may also be used for treatment of a plant propagation material such as seeds etc.

The compositions of the present invention may be applied in any known ways or conventional methods known to a person skilled in art. Non-limiting examples of such methods are foliar spray, basal barking, stem injection, drill and fill method, axe cut method, cut stump, cut and swab, stem scraper, wick application and so forth. The compositions of the present invention are used in the customary manner, for example by watering, spraying, atomizing, dusting or scattering. Said compositions can be applied to a locus by the use of conventional ground sprayers, granule applicators, watering (drenching), drip irrigation, spraying, atomizing, broadcasting, dusting, foaming, spreading-on, aerial methods of spraying, aerial methods of application, methods utilizing application using modern technologies such as, but not limited to, drones, robots and by other conventional means known to those skilled in the art.

In an embodiment, the present invention provides a method of controlling the growth of undesirable vegetation, the method comprising treating the locus at which control is desired with combinations or synergistic combinations of the present invention or compositions comprising said combinations.

In an embodiment, the present invention provides a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with an herbicidal combination or a composition comprising said combination, wherein the combination comprises glufosinate, salts or esters thereof, and at least two herbicides selected from:

a) nitrophenyl ether class of herbicides;
b) imidazolinone class of herbicides;

c) organophosphorous class of herbicides;
d) dicarboximide class of herbicides;
e) phenoxyacetic class of herbicides;
f) pyridine class of herbicides;
g) cyclohexene oxime class of herbicides;
h) aryloxyphenoxypropionic class of herbicides;
i) triazolone class of herbicides; and/or
j) uracil class of herbicides.

In an embodiment, the present invention provides a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with an herbicidal combination or a composition comprising said combination, wherein the combination comprises comprising L-glufosinate, salts or esters thereof, and at least two herbicides selected from:

a) nitrophenyl ether class of herbicides;
b) imidazolinone class of herbicides;
c) organophosphorous class of herbicides;
d) dicarboximide class of herbicides;
e) phenoxyacetic class of herbicides;
f) pyridine class of herbicides;
g) cyclohexene oxime class of herbicides;
h) aryloxyphenoxypropionic class of herbicides;
i) triazolone class of herbicides; and/or
j) uracil class of herbicides.

In an embodiment, the present invention provides a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic herbicidal combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:

k) nitrophenyl ether class of herbicides;
l) imidazolinone class of herbicides;
m) organophosphorous class of herbicides;
n) dicarboximide class of herbicides;
o) phenoxyacetic class of herbicides;

p) pyridine class of herbicides;
q) cyclohexene oxime class of herbicides;
r) aryloxyphenoxypropionic class of herbicides;
s) triazolone class of herbicides;
t) uracil class of herbicides,

or combinations thereof.

In an embodiment, the present invention provides a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic herbicidal combination comprising L-glufosinate, salts or esters thereof, and at least two herbicides selected from:

k) nitrophenyl ether class of herbicides;
l) imidazolinone class of herbicides;
m) organophosphorous class of herbicides;
n) dicarboximide class of herbicides;
o) phenoxyacetic class of herbicides;
p) pyridine class of herbicides;
q) cyclohexene oxime class of herbicides;
r) aryloxyphenoxypropionic class of herbicides;
s) triazolone class of herbicides;
t) uracil class of herbicides,

or combinations thereof.

In an embodiment, the present invention provides a method for increasing yield in a crop by using the combinations of the present invention. Therefore, in an embodiment, the present invention provides a method for increasing yield in a crop by application of a combination or composition comprising – glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;

(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides; and/or
(j) uracil class of herbicides.

In an embodiment, the present invention provides a method for improving the plant health using the combinations of the present invention. Therefore, in an embodiment, the present invention provides a method for improving the plant health by application of a combination or composition comprising – glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides selected from:

(a) nitrophenyl ether class of herbicides;
(b) imidazolinone class of herbicides;
(c) organophosphorous class of herbicides;
(d) dicarboximide class of herbicides;
(e) phenoxyacetic class of herbicides;
(f) pyridine class of herbicides;
(g) cyclohexene oxime class of herbicides;
(h) aryloxyphenoxypropionic class of herbicides;
(i) triazolone class of herbicides; and/or
(j) uracil class of herbicides

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the weight ratio of glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and the at least two herbicides is 1:100:100 to 100:1:1, preferably 1:75:75 to 75:1:1, more preferably 1:50:50 to 50:1:1 and even more preferably 1:25:25 to 25:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the weight ratio of glufosinate, salts or esters

thereof or L-glufosinate, salts or esters thereof, and one of the two herbicides is 1:100 to 100:1, preferably 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides, wherein the weight ratio of the two herbicides is 1:100 to 100:1, preferably 1:75 to 75:1, more preferably 1:50 to 50:1 and even more preferably 1:25 to 25:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the imidazolinone class of herbicides, and a herbicide selected from the triazolone class of herbicides.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the imidazolinone class of herbicides, and a herbicide selected from the triazolone class of herbicides, wherein glufosinate, salts or esters thereof, the herbicide selected from the imidazolinone class of herbicides, and the herbicide selected from the triazolone class of herbicides are present in a ratio of 1:100:100 to 100:1:1, more preferably 1:10:10 to 10:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof; a herbicide selected from the imidazolinone class of herbicides; and a herbicide selected from the triazolone class of herbicides, wherein the imidazolinone class herbicide is imazethapyr and the triazolone class herbicide is carfentrazone.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, imazethapyr and carfentrazone, wherein the weight ratio of glufosinate, salts or esters

thereof, imazethapyr and carfentrazone is 1:10:10 to 10:1:1, preferably 1:5:5 to 5:1:1, more preferably 1:2:2 to 2:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the phenoxyacetic class of herbicides, and a herbicide selected from the uracil class of herbicides.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the phenoxyacetic class of herbicides, and a herbicide selected from the uracil class of herbicides, wherein glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, the herbicide selected from the phenoxyacetic class of herbicides, and the herbicide selected from the uracil class of herbicides are present in a ratio of 1:100:100 to 100:1:1, more preferably 1:10:10 to 10:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof; a herbicide selected from the phenoxyacetic class of herbicides; and a herbicide selected from the uracil class of herbicides, wherein the phenoxyacetic class herbicide is 2,4-D and the uracil class herbicide is saflufenacil.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, 2,4-D and saflufenacil, wherein the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, 2,4-D and saflufenacil is 1:10:10 to 10:1:1, preferably 1:5:5 to 5:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the pyridine class of herbicides, and a herbicide selected from the uracil class of herbicides.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a herbicide selected from the pyridine class of herbicides, and a herbicide selected from the uracil class of herbicides, wherein glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, the herbicide selected from the pyridine class of herbicides, and the herbicide selected from the uracil class of herbicides are present in a ratio of 1:100:100 to 100:1:1, more preferably 1:10:10 to 10:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof; a herbicide selected from the pyridine class of herbicides; and a herbicide selected from the uracil class of herbicides, wherein the pyridine class herbicide is triclopyr and the uracil class herbicide is saflufenacil.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, triclopyr and saflufenacil, wherein the weight ratio of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, triclopyr and saflufenacil is 1:10:10 to 10:1:1, preferably 1:5:5 to 5:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and two herbicides selected from the imidazolinone class of herbicides.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and two herbicides selected from the imidazolinone class of herbicides, wherein glufosinate, salts or esters thereof, or L- glufosinate, salts or esters thereof and the two herbicides selected from the imidazolinone class of herbicides are present in a ratio of 1:100:100 to 100:1:1, more preferably 1:10:10 to 10:1:1.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof; and two herbicides selected from the imidazolinone class of herbicides; wherein the imidazolinone class herbicides are imazapic and imazapyr.

In an embodiment, the present invention provides for a method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with a synergistic combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, imazapic and imazapyr, wherein the weight ratio of glufosinate, salts or esters thereof, or L- glufosinate, salts or esters thereof, imazapic and imazapyr is 1:10:10 to 10:1:1, preferably 1:5:5 to 5:1:1.

The terms "g ai/h" as used herein denotes the concentration of the respective active ingredient in "grams" applied "per hectare" of the crop field.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the combination or composition comprises glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, in an amount in the range of 100 to 400 g ai/L, preferably 180 to 380 g ai/L, more preferably 250 to 350 g ai/L. In a preferred embodiment, the composition comprises 280 g ai/L of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof and at least two herbicides or a composition comprising said combination, wherein glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof is applied at an application rate of 50- 350 g ai/h, preferably 100 g ai/h to 250 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from nitrophenyl ether class of herbicides, and wherein the nitrophenyl ether class of herbicides is present in the composition

in an amount in the range of 100 to 400 g ai/L, preferably 140 to 340 g ai/L, more preferably 200 to 250 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from nitrophenyl ether class of herbicides, and wherein the nitrophenyl ether class of herbicides is applied at an application rate of 5-250 g ai/h, preferably at a rate of 50-150 g ai/h and more preferably at a rate of 75–125 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the composition in an amount in the range of 10 to 250 g ai/L, preferably 50 -200 g ai/L, more preferably 75 -125 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is present in the composition in an amount in the range of 100 to 1000 g ai/L, preferably 100 - 800 g ai/L..

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from imidazoline class of herbicides, and wherein the imidazoline class of herbicides is applied at an application rate of 5-200 g ai/h, preferably at a rate of 10 to 150 g ai/h and more preferably at a rate of 10 - 100 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from organophosphorous class of herbicides, and wherein the organophosphorous class of herbicides is present in the

composition in an amount in the range of 200 to 1000 g ai/L, preferably 400 to 800 g ai/L, more preferably 500 - 700 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from organophosphorous class of herbicides, and wherein the organophosphorous class of herbicides is applied at an application rate of 100-800 g ai/h, preferably at a rate of 200 – 500 g ai/h, more preferably 300-400 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from dicarboximide class of herbicides, and wherein the dicarboximide class of herbicides is present in the composition in an amount in the range of 200 – 800 g ai/L, preferably 300 to 700 g ai/L, more preferably 400-600 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from dicarboximide class of herbicides, and wherein the dicarboximide class of herbicides is applied at an application rate of 1 to 200 g ai/h, preferably 5-100 g ai/h, more preferably at a rate of 10 - 50 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is present in the composition in an amount in the range of 200 to 1200 g ai/L, preferably 400 - 1000 g ai/L, more preferably 450 – 850 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from phenoxyacetic class of

herbicides, and wherein the phenoxyacetic class of herbicides is present in the composition in an amount in the range of 400 to 1200 g ai/L, preferably 600 - 1000 g ai/L, more preferably 750 – 850 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from phenoxyacetic class of herbicides, and wherein the phenoxyacetic class of herbicides is applied at an application rate of 50 – 400 g ai/h, preferably 100 - 300 g ai/h, more preferably at a rate of 150-250 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the composition in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 400 to 750 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is present in the composition in an amount in the range of 300 – 1000 g ai/L, preferably 400 to 900 g ai/L, more preferably 500 to 750 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from pyridine class of herbicides, and wherein the pyridine class of herbicides is applied at an application rate of 50-500 g ai/h, preferably at a rate of 100-400 g ai/h and more preferably 200-350 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from cyclohexene oxime class of herbicides, and wherein the cyclohexene oxime class of herbicides is present in the composition

in an amount in the range of 100 – 400 g ai/L, preferably 150 to 350 g ai/L, more preferably 200-300 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from cyclohexene oxime class of herbicides, and wherein the cyclohexene oxime class of herbicides is applied at an application rate of 1-150 g ai/h, preferably at a rate of 10 – 100 g ai/h, more preferably 25-75 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from aryloxyphenoxypropionic class of herbicides, and wherein the aryloxyphenoxypropionic class of herbicides is present in the composition in an amount in the range of 1 to 250 g ai/L, preferably 10 – 200 g ai/L and more preferably 50 – 150 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from aryloxyphenoxypropionic class of herbicides, and wherein the aryloxyphenoxypropionic class of herbicides is applied at an application rate of 1-150 g ai/h, preferably at a rate of 10 – 100 g ai/h, more preferably 25-75 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from triazolone class of herbicides, and wherein the triazolone class of herbicides is present in the composition in an amount in the range of 100 – 800 g ai/L, preferably 200 to 600 g ai/L, more preferably 300 to 500 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from triazolone class of herbicides,

and wherein the triazolone class of herbicides is applied at an application rate of 0.5-100 g ai/h, preferably at a rate of 1 – 50 g ai/h, more preferably 2-30 g ai/h.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from uracil class of herbicides, and wherein the uracil class of herbicides is present in the composition in an amount in the range of 1 – 1000 g ai/L, preferably 50 to 800 g ai/L.

In an embodiment, the present invention provides a method of controlling weeds at a locus by treating said locus with a combination of glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and at least two herbicides or a composition comprising said combination, wherein the at least one herbicide is selected from uracil class of herbicides, and wherein the uracil class of herbicides is applied at an application rate of 10-150 g ai/h, preferably at a rate of 20-70 g ai/h.

The compositions of the present invention can be used in agricultural lands such as fields, paddy fields, lawns and orchards or in non-agricultural lands. The present invention may be used to control diseases in agricultural lands for cultivating the plants without any phytotoxicity to the plant. Examples of the crops on which the present compositions may be used include but are not limited to corn, rice, wheat, barley, rye, oat, sorghum, cotton, soybean, peanut, buckwheat, beet, rapeseed, sunflower, sugar cane, tobacco, etc.; vegetables: solanaceous vegetables such as eggplant, tomato, pimento, pepper, potato, etc., cucurbit vegetables such as cucumber, pumpkin, zucchini, water melon, melon, squash, etc., cruciferous vegetables such as radish, white turnip, horseradish, kohlrabi, Chinese cabbage, cabbage, leaf mustard, broccoli, cauliflower, etc., asteraceous vegetables such as burdock, crown daisy, artichoke, lettuce, etc, liliaceous vegetables such as green onion, onion, garlic, and asparagus, ammiaceous vegetables such as carrot, parsley, celery, parsnip, etc., chenopodiaceous vegetables such as spinach, Swiss chard, etc., lamiaceous vegetables such as *Perilla frutescens*, mint, basil, etc, strawberry, sweet potato, *Dioscorea japonica*, colocasia, etc., flowers, foliage plants, turf grasses, fruits: pome fruits such apple, pear, quince, etc, stone fleshy fruits such as peach, plum, nectarine, *Prunus mume*, cherry fruit, apricot, prune, etc., citrus fruits such as orange, lemon, rime, grapefruit, etc., nuts such as chestnuts, walnuts, hazelnuts, almond, pistachio, cashew nuts, macadamia nuts, etc. berries such as blueberry, cranberry, blackberry,

raspberry, etc., grape, kaki fruit, olive, plum, banana, coffee, date palm, coconuts, etc. , trees other than fruit trees; tea, mulberry, flowering plant, trees such as ash, birch, dogwood, Eucalyptus, *Ginkgo biloba*, lilac, maple, Quercus, poplar, Judas tree, *Liquidambar formosana*, plane tree, zelkova, Japanese arborvitae, fir wood, hemlock, juniper, Pinus, Picea, and Taxus cuspidate, etc.

In an embodiment, the combinations or the compositions of the present invention may be used for controlling a wide range of weeds such as *Glycine max, Borreria verticillate, Eleusine indica, Amaranthus viridus, Lolium spp, Euphorbia heterophylla, Spermacoce verticillate, Spermacoce latifolia, and Brachiaria decumbens*.

Examples of weeds controlled by the composition of the invention include, but are not limited to: Annual mercury, Black bindweed, Black medick, Black nightshade, Canadian fleabane, Charlock, Cleavers, Common amaranth, Common chickweed, Common fiddleneck, Common field-speedwell, Common fumitory, Common hemp-nettle, Common orache, Common poppy, Corn chamomile, Corn marigold, Corn spurrey, Cut-leaved crane's-bill, Dove's-foot crane's-bill, Dwarf spurge, Fat-hen, Field forget-me-not, Field Madder, Field pansy, Field penny-cress, Flixweed, Fool's parsley, Gallant soldiers, Garlic mustard, Groundsel, Hairy bittercress, Hairy Tare, Hedge mustard, Henbit dead-nettle, Himalayan balsam, Ivy-leaved speedwell, Knotgrass, Lesser trefoil, Long-headed poppy, Nipplewort, Oxford ragwort, Pale persicaria, Parsley piert, Petty spurge, Pineappleweed, Prickly lettuce, Prickly sow-thistle, Red dead-nettle, Redshank, Scarlet pimpernel, Scented mayweed, Scentless mayweed, Shepherd's purse, Small nettle, Smooth hawk's-beard, Smooth sow-thistle, Spear-leaved orache, Sticky mouse-ear, Stinking chamomile, Sun spurge, Swine cress, Thale cress, Thorn-apple, Wall speedwell, Wild radish, Annual meadow-grass, Barren brome, Black-grass, Soft brome, Wall Barley, Wild-oat, Winter wild-oat, Caper spurge, Evening-primrose, Giant hogweed, Goat's-beard, Hemlock, Hogweed, Spear thistle, Bracken, Field horsetail, Rushes, Bramble, Broad-leaved dock, Bulbous buttercup, Cat's-ear, Coltsfoot, Common mouse-ear, Common nettle, Common ragwort, Common sorrel, Common toadflax, Cow parsley, Creeping buttercup, Creeping thistle, Curled dock, Daisy, Dandelion, Field bindweed, Greater plantain, Ground elder, Ground-ivy, Hedge bindweed, Hoary cress, Japanese knotweed, Lesser celandine, Meadow buttercup, Mouse-ear-hawkweed, Mugwort, Perennial sowthistle, Perforate St John, Procumbent pearlwort, Ribwort plantain, Rosebay willowherb, Selfheal, Sheep's sorrel, Slender speedwell, Thyme-leaved speedwell, White campion, White clover, Yarrow, Black bent, Cock's-foot, Common bent, Common couch, Creeping bent, Creeping soft-grass, Onion couch, Perennial rye-grass, Rough

meadow-grass, Yorkshire fog, Volunteer cereals, Volunteer oilseed rape, Volunteer Potato, Weed Beet, Alopecurus myosuroides Huds. (blackgrass, ALOMY), Amaranthus palmeri (Palmer amaranth, AMAPA) Amaranthus viridis (slender amaranth, AMAVI), Avena fatua (wild oat, AVEFA), Brachiaria decumbens Stapf. or Urochloa decumbens (Stapf), Brachiaria brizantha or Urochloa brizantha, Brachiaria platyphylla (Groseb.) Nash or Urochloa platyphylla (broadleaf signalgrass, BRAPP), Brachiaria plantaginea. or Urochloa plantaginea (alexandergrass, BRAPL), Cenchrus echinatus (southern sandbur, CENEC), Digitaria horizontalis Willd. (Jamaican crabgrass, DIGHO), Digitaria insularis (sourgrass, TRCIN), Digitaria sanguinalis (large crabgrass, DIGSA), Echinochloa crus-galli (barnyardgrass, ECHCG), Echinochloa colonum (junglerice, ECHCO), Eleusine indica Gaertn. (goosegrass, ELEIN), Lolium multiflorum Lam. (Italian ryegrass, LOLMU), Panicum dichotomiflorum Michx. (fall panicum, PANDI), Panicum miliaceum L. (wild-proso millet, PANMI), Sesbania exaltata (hemp sesbania, SEBEX), Setaria faberi Herrm. (giant foxtail, SETFA), Setaria viridis (green foxtail, SETVI), Sorghum halepense (Johnsongrass, SORHA), Sorghum bicolor, Moench ssp., Arundinaceum (shattercane, SORVU), Cyperus esculentus (yellow nutsedge, CYPES), Cyperus rotundus (purple nutsedge, CYPRO), Abutilon theophrasti (velvetleaf, ABUTH), Amaranthus species (pigweeds and amaranths, AMASS), Ambrosia artemisiifolia L. (common ragweed, AMBEL), Ambrosia psilostachya DC. (western ragweed, AMBPS), Ambrosia trifida (giant ragweed, AMBTR), Anoda cristata (spurred anoda, ANVCR), Asclepias syriaca (common milkweed, ASCSY), Bidens pilosa (hairy beggarticks, BIDPI), Borreria species (BOISS), Borreria alata or Spermacoce alata Aubl. or Spermacoce latifolia (broadleaf buttonweed, BOILF), Chenopodium album L. (common lambsquarters, CHEAL), Cirsium arvense (Canada thistle, CIRAR), Commelina benghalensis (tropical spiderwort, COMBE), Datura stramonium (jimsonweed, DATST), Daucus carota (wild carrot, DAUCA), Euphorbia heterophylla (wild poinsettia, EPHHL), Euphorbia hirta or Chamaesyce hirta (garden spurge, EPHHI), Euphorbia dentata Michx. (toothed spurge, EPHDE), Erigeron bonariensis or Conyza bonariensis (hairy fleabane, ERIBO), Erigeron canadensis or Conyza canadensis (horseweed, ERICA), Conyza sumatrensis (tall fleabane, ERIFL), Helianthus annuus (common sunflower, HELAN), Jacquemontia tamnifolia (smallflower morningglory, IAQTA), Ipomoea hederacea (ivyleaf morningglory, IPOHE), Ipomoea lacunosa (white morningglory, IPOLA), Lactuca serriola (prickly lettuce, LACSE), Portulaca oleracea (common purslane, POROL), Richardia species (pusley, RCHSS), Salsola tragus (Russian thistle, SASKR), Sida species (sida, SIDSS), Sida spinosa (prickly sida, SIDSP), Sinapis arvensis (wild mustard, SINAR), Solanum ptychanthum (eastern black nightshade, SOLPT),

Tridax procumbens (coat buttons, TRQPR), Rumex dentatus (RUMDE)or Xanthium strumarium (common cocklebur, XANST), crabgrass complex (Digitaria horizontalis, Digitaria nuda and others), guinea grass (Panicum maximum), Surinam grass (Brachiaria decumbens), morning glories (Ipomoea grandifolia, Ipomoea nil, Ipomoea quamoclit, Ipomoea purpurea, Ipomoea hederifolia, Merremia cissoides and Merremia aegypta), beggar-ticks (Bidens pilosa), Java grass or purple nut sedge (Cyperus rotundus and Cyperus spp), Indian goosegrass or crowfoot grass (Eleusine indica), southern sandbur (Cenchrus echinatus), velvet bean or mucuna (Mucuna pruriens), wild poinsettia or milkweed (Euphorbia heterophylla), Paraguayan starbur (Acanthospermum australe), Slender amaranth (Amaranthus viridis), Alexandergrass (Brachiaria plantaginea), Benghal dayflower (Commelina benghalensis), Lilac tasselflower (Emilia sonchifolia), Wild poinsettia or milkweed (Euphorbia heterophylla), Gallant soldier (Galinsoga parviflora), Purslane or pigweed (Portulaca oleracea), Brazilian calla-lily or Brazil pusley (Richardia brasiliensis), Flannel weed (Sida cordifolia), Southern sida (Sida glaziovii), Southern sida (Sida rhombifolia), Buttonweed or broad-leaved buttonweed (Spermacoce latifólia).

In a preferred embodiment, the weeds controlled by the combinations/compositions of the present invention include weedy *Glycine max, Spermacoce latifolia, Eleusine indica* and *Brachiaria decumbens.*

In a preferred embodiment, the weeds controlled by the combinations/compositions of the present invention include *Borreria verticillata, Euphorbia heterophylla, Lolium* spp., and *Amaranthus* spp.

The combinations of the present invention may be sold as a pre-mix composition or a kit of parts such that individual actives may be mixed before spraying. Alternatively, the kit of parts may contain the at least two herbicides pre-mixed and the glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, packaged separately, such that the components may be tank mixed before spraying.

The method of control of the present invention may be carried out by spraying the suggested tank mixes, or the individual herbicides may be formulated as a kit-of-parts containing various components that may be mixed as instructed prior to spraying.

In an embodiment, the present invention provides a kit-of-parts comprising a plurality of

components, wherein said plurality of components comprises:

a) a first component as glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof;

b) a second component comprising a herbicide selected from nitrophenyl ether, imidazolinone, organophosphorous, dicarboximide, phenoxyacetic, pyridine, cyclohexene oxime, aryloxyphenoxypropionic, triazolone, or uracil class of herbicides; and

c) a third component comprising a herbicide selected from nitrophenyl ether, imidazolinone, organophosphorous, dicarboximide, phenoxyacetic, pyridine, cyclohexene oxime, aryloxyphenoxypropionic, triazolone, or uracil class of herbicides.

In an embodiment, the kit-of-parts comprises an instructions manual, said instructions manual comprising instructions directing a user to admix the components before being used.

In an embodiment, each of the components of the present invention may be packaged separately and may be tank mixed at the time of spraying.

In another embodiment, the components of the present invention may be packaged as composition such that the glufosinate, salts or esters thereof or L-glufosinate, salts or esters thereof, and the at least two herbicides are formulated into one composition and other additives are packaged separately, such that the two maybe tank mixed at the time of spraying.

Surprisingly, it has been found by the present inventors, that when glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and the at least two herbicides of the present invention, when applied individually, was ineffective in the control of weeds, but demonstrated excellent synergistic control on when applied together. The current invention therefore provides advantageous combinations, compositions and methods of controlling weeds.

The combinations of the present invention or compositions comprising the said combinations maybe applied simultaneously as a tank mix or a formulation or may be applied sequentially. The combinations may be a tank mixes of compositions of individual active ingredients. The application may be made as a foliar spray at different timings during crop development, with either one or two applications early or late post-emergence.

The present invention is more particularly described in the following examples that are intended as illustration only, since numerous modifications and variations within the scope of the present invention will be apparent to those of skill in the art. Unless otherwise noted, all parts, percentages, and ratios reported in the following examples are on a weight basis, and all reagents used in the examples were obtained or are available from the chemical suppliers.

The following examples illustrates the composition, underlying effect and basic methodology of the present invention.

Examples:

The following examples demonstrate the present invention.

Composition:

A combination of L-glufosinate, Imazethapyr and carfentrazone was prepared with the following dosage of active ingredients (a.i.)

Active ingredient	Amount a.i., g/L
L-glufosinate	280
Imazethapyr	106
Carfentrazone	400

A combination of L-glufosinate, triclopyr and safluenacil was prepared with the following dosage of active ingredients (a.i.)

Active ingredient	Amount a.i., g/L
L-glufosinate	280
Triclopyr	480
Saflufenacil	700

A combination of L-glufosinate, 2,4D and saflufenacil was prepared with the following dosage of active ingredients (a.i.)

Active ingredient	Amount a.i., g/L
L-glufosinate	280

2,4D	456
Saflufenacil	700

A combination of L-glufosinate, imazapic and imazapyr was prepared with the following dosage of active ingredients (a.i.)

Active ingredient	Amount a.i., g/L
L-glufosinate	280
Imazapic + imazapyr	525 + 175

Evaluation of Post-emergence Herbicidal Activity of combinations under Field Conditions

Methodology: Greenhouse trials were carried out to evaluate the efficacy of the combination of L-glufosinate and the other herbicides on weeds such as *Glycine max, Spermacoce verticilata, Eleusine indica, Brachiaria decumbens*. The soil used was sandy clay loam - Sand: 68,0%; Silt: 8,0%; Clay: 24,0%. All treatments were conducted in 4 replications per treatment with a spray volume of 150 L/h.

Evaluation

The expected efficacy of a combination of L-glufosinate and the other herbicides was calculated using the well-established Colby method. Any difference between the observed and "expected" efficacy could be attributed to synergy between the two compounds.

In the Colby method, the expected (or predicted) response of a combination of herbicides is calculated by taking the product of the observed response for each individual component of the combination when applied alone, divided by 100, and subtracting this value from the sum of the observed response for each component when applied alone. An unexpected enhancement in efficacy of the combination is then determined by comparing the observed response of the combination to the expected (or predicted) response as calculated from the observed response of each individual component alone. If the observed response of the combination is greater than the expected (or predicted) response, or stated conversely, if the difference between the observed and expected response is greater than zero, then the combination is said to be

synergistic or unexpectedly effective (Colby, S. R., Weeds, 1967(15), p. 20-22). The Colby method requires only a single dose of each herbicide applied alone and the mixture of both doses. The formula used to calculate the expected efficacy (EE) which was compared with the observed efficacy (OE) to determine the efficacy of the present invention is explained hereinbelow:

The expected efficacy for a combination of two active ingredients is as follows:

$$EE = (A + B - (A \times B)/100)$$

The expected efficacy for a combination of three active ingredients is as follows:

$$EE = A + B + C - (AB + AC + BC)/100 + ABC/10{,}000$$

Where,

A = Observed efficacy of active ingredient A at the same concentration as used in the mixture.

B = Observed efficacy of the active ingredient B at the same concentration as used in the mixture.

C = Observed efficacy of the active ingredient C at the same concentration as used in the mixture.

Table 3: Table 3 demonstrates synergy on weeds using the combination of L-glufosinate, imazethapyr and carfentrazone. The percentage efficacy was calculated for 14, 21, 28, 35 days of applications (DAA). The target weed was weedy *Glycine max*, and the concentration of the herbicide and the results are recorded the table 3 below:

Active ingredient, dose a.i., g/h	**14 DAA**		**21 DAA**		**28 DAA**		**35 DAA**	
	Control%	Colby*	Control %	Colby*	Control%	Colby*	Control%	Colby*
L-glufosinate, 150	60	-	63.3	-	63.3	-	52.7	-
Imazethapyr, 75.0	10	-	20.0	-	20.0	-	15.0	-
Carfentrazone, 7.5	50.3	-	44.3	-	44.3	-	39.3	-

L-glufosinate, 150 + imazethapyr, 75 + carfentrazone, 7.5	89.3	82.1	95.3	83.6	96.7	83.6	96.0	75.6

**Expected control according to Colby's Formula*

Table 4: Table 4 demonstrates synergy on weeds using the combination of L-glufosinate, imazethapyr and carfentrazone. The percentage efficacy was calculated for 3, 7, 14, 21, 28, 35 days of applications (DAA). The target weed was weedy *Eleusine indica*, and the concentration of the herbicide and the results are recorded the table 4 below:

Active ingredient, dose a.i., g/h	**3 DAA**		**7 DAA**		**14 DAA**		**21 DAA**		**28 DAA**		**35 DAA**	
	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*
L-glufosinate, 150	15		43.3		41.3		37.3		28.3		25.3	
Imazethapyr, 75.0	3.7		8.3		12		12.7		12.7		10	
Carfentrazone, 7.5	8.7		14		12.3		11		7.7		0	
L-glufosinate, 150 + imazethapyr, 75 + carfentrazone, 7.5	33.3	25.3	69.3	55.3	84.3	54.7	86.7	51.3	84.7	42.2	82.7	32.8

**Expected control according to Colby's Formula*

Table 5: Table 5 demonstrates synergy on weeds using the combination of L-glufosinate, imazethapyr and carfentrazone. The percentage efficacy was calculated for 7, 14, 21, 28, 35 days of applications (DAA). The target weed was weedy *Spermacoce latifolia*, and the concentration of the herbicide and the results are recorded the table 5 below:

Active ingredient, dose a.i., g/h	7 DAA		14 DAA		21 DAA		28 DAA		35 DAA	
	Control %	Colby*	Control %	Colby*	Control %	Colby*	Control %	Colby*	Control %	Colby*
L-glufosinate, 150	35		56.7		56.7		58.3		58.3	
Imazethapyr, 75.0	13.3		30		36.7		30		26.7	
Carfentrazone, 7.5	58.3		64.3		64.3		64.3		63.3	
L-glufosinate, 150 + imazethapyr, 75 + carfentrazone, 7.5	89	76.5	99.7	89.2	99.7	90.2	100	89.6	100	88.8

**Expected control according to Colby's Formula*

Table 6: Table 6 demonstrates synergy on weeds using the combination of L-glufosinate, imazethapyr and carfentrazone. The percentage efficacy was calculated for 7, 14, 21, 28, 35 days of applications (DAA). The target weed was weedy *Brachiaria decumbens*, and the concentration of the herbicide and the results are recorded the table 6 below:

Active ingredient, dose a.i., g/h	7 DAA		14 DAA		21 DAA		28 DAA		35 DAA	
	Control %	Colby*	Control %	Colby*	Control %	Colby*	Control %	Colby*	Control %	Colby*
L-glufosinate, 150	46		54.3		53.3		48.3		42	

Imazethapyr, 75.0	10		10		15		10		5	
Carfentrazone, 7.5	14		16.7		15		5		0	
L-glufosinate, 150 + imazethapyr, 75 + carfentrazone, 7.5	66	58.2	84.3	65.7	90	66.3	87.7	55.8	85.7	44.9

**Expected control according to Colby's Formula*

Table 7: Table 7 demonstrates synergy on weeds using the combination of L-glufosinate, triclopyr and saflufenacil. The percentage efficacy was calculated for 7 days of applications (DAA). The target weed was weedy *Glycine max*, and the concentration of the herbicide and the results are recorded the table 7 below:

Active ingredient, dose a.i., g/h	7 DAA	
	Control%	Colby*
L-glufosinate, 150	71.9	
Saflufenacil, 30	75.4	
Triclopyr, 228	67.9	
L-glufosinate, 150 + Saflufenacil, 30 + Triclopyr, 228	100	97.7

**Expected control according to Colby's Formula*

Table 8: Table 8 demonstrates synergy on weeds using the combination of L-glufosinate, triclopyr and saflufenacil. The percentage efficacy was calculated for 3 days of applications (DAA). The target weed was *Brachiaria decumbens*, and the concentration of the herbicide and the results are recorded the table 8 below:

Active ingredient, dose a.i., g/h	7 DAA	
	Control%	Colby*
L-glufosinate, 150	66.2	
Saflufenacil, 30	30	

Triclopyr, 228	0	
L-glufosinate, 150 + Saflufenacil, 30 + Triclopyr, 228	77.5	76.3

**Expected control according to Colby's Formula*

Table 9: Table 9 demonstrates synergy on weeds using the combination of L-glufosinate, 2,4D and saflufenacil. The percentage efficacy was calculated for 21, 28 and 35 days of applications (DAA). The target weed was weedy *Glycine max*, and the concentration of the herbicide and the results are recorded the table 9 below:

Active ingredient, dose a.i., g/h	**21 DAA**		**28 DAA**		**35 DAA**	
	Control%	Colby*	Control%	Colby*	Control%	Colby*
L-glufosinate, 150	57.5		50.6		47.5	
Saflufenacil, 30	63.2		52.5		50.7	
2,4D, 228	49.3		43.8		41	
L-glufosinate, 150 + Saflufenacil, 30 + 2,4D, 228	100	92	100	86.8	100	84.7

**Expected control according to Colby's Formula*

Table 10: Table 10 demonstrates synergy on weeds using the combination of L-glufosinate, imazapic and imazapyr. The percentage efficacy was calculated for 3, 7, 14, 21, 28 and 35 days of applications (DAA). The target weed was *Borreria verticillata*, and the concentration of the herbicide and the results are recorded the table 10 below:

Active ingredient, dose a.i., g/h	**3 DAA**		**7 DAA**		**14 DAA**		**21 DAA**		**28 DAA**		**35 DAA**	
	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*	Control%	Colby*
L-glufosi	50		80		95		90		90		85	

nate, 150												
Imazapic and Imazapyr, 31.5 + 10.5	15		20		30		30		40		55	
L-glufosinate, 150 + Imazapic and Imazapyr, 31.5 + 10.5	70	57.5	95	84	100	96.5	100	93	100	94	100	93.25

**Expected control according to Colby's Formula*

Table 11: Table 11 demonstrates synergy on weeds using the combination of L-glufosinate, imazapic and imazapyr. The percentage efficacy was calculated for 3 days of applications (DAA). The target weed was *Amaranthus viridus*, and the concentration of the herbicide and the results are recorded the table 11 below:

Active ingredient, dose a.i., g/h	3 DAA	
	Control%	Colby*
L-glufosinate, 150	50	
Imazapic and Imazapyr, 31.5 + 10.5	35	
L-glufosinate, 150 + Imazapic and Imazapyr, 31.5 + 10.5	70	67.5

**Expected control according to Colby's Formula*

Table 12: Table 12 demonstrates synergy on weeds using the combination of L-glufosinate, imazapic and imazapyr. The percentage efficacy was calculated for 3, 7, 14 days of applications (DAA). The target weed was *Eleusine indica*, and the concentration of the herbicide and the results are recorded the table 12 below:

Active ingredient, dose a.i., g/h	**3 DAA**		**7 DAA**		**14 DAA**	
	Control%	Colby*	Control%	Colby*	Control%	Colby*
L-glufosinate, 150	40		50		40	
Imazapic and Imazapyr, 31.5 + 10.5	10		15		40	
L-glufosinate, 150 + Imazapic and Imazapyr, 31.5 + 10.5	50	46	65	57.5	70	64

**Expected control according to Colby's Formula*

The results in table 3-12 demonstrate the synergy between L-glufosinate, and two herbicides. The large difference between the observed and the expected efficacy clearly demonstrates the synergistic effect of the combination.

While the foregoing written description of the invention enables one of ordinary skill to make and use what is considered presently to be the best mode thereof, those of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiment, method, and examples herein. The invention should therefore not be limited by the above-described embodiment, method, and examples, but by all embodiments and methods within the scope and spirit of the invention.

We Claim:

1. An herbicidal combination comprising glufosinate, salts or esters thereof, and at least two herbicides selected from:
   (a) nitrophenyl ether class of herbicides;
   (b) imidazolinone class of herbicides;
   (c) organophosphorous class of herbicides;
   (d) dicarboximide class of herbicides;
   (e) phenoxyacetic class of herbicides;
   (f) pyridine class of herbicides;
   (g) cyclohexene oxime class of herbicides;
   (h) aryloxyphenoxypropionic class of herbicides;
   (i) triazolone class of herbicides; and/or
   (j) uracil class of herbicides.

2. The combination as claimed in claim 1, wherein the glufosinate, salts or esters thereof is L- glufosinate, salts or esters thereof.

3. The combination as claimed in claim 1, wherein the second and third herbicides are selected from within the different classes of herbicides.

4. The combination as claimed in claim 1, wherein the second and third herbicides are selected from within the same class of herbicides.

5. The combination as claimed in claim 1, wherein the weight ratio of glufosinate, salts or esters thereof and the at least two herbicides ranges from 1:100:100 to 100:1:1.

6. The combination as claimed in claim 1, wherein the weight ratio of glufosinate, salts or esters thereof and one of the two herbicides ranges from 1:100 to 100:1.

7. The combination as claimed in claim 1, wherein:
   (a) the nitrophenyl ether class herbicide is selected from the group consisting of oxyfluorfen, acifluorfen, aclonifen, bifenox, chlomethoxyfen, chlornitrofen,

etnipromid, fluorodifen, fluoroglycofen, fluoronitrofen, fomesafen, fucaomi, furyloxyfen, halosafen, lactofen, nitrofen, nitrofluorfen, and combinations thereof;

(b) the imidazolinone class herbicide is selected from the group consisting of imazethapyr, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, and combinations thereof;

(c) the organophosphorous class herbicide is selected from the group consisting of glyphosate, amiprofos-methyl, amiprophos, anilofos, bensulide, bilanafos, butamifos, clacyfos, 2,4-DEP, DMPA ((O-(2,4-dichlorophenyl) O-methyl isopropylphosphoramidothioate)), EBEP (ethyl bis(2-ethylhexyl)phosphinate), fosamine, glufosinate-P, piperophos, and combinations thereof;

(d) the dicarboximide class herbicide is selected from the group consisting of cinidon-ethyl, flumezin, flumiclorac, flumioxazin, flumipropyn, and combinations thereof;

(e) the phenoxyacetic class herbicide is selected from the group consisting of clacyfos, 4-CPA (p-Chlorophenoxyacetic acid), 2,4-D, 3,4-DA, MCPA (2-methyl-4-chlorophenoxyacetic acid), MCPA-thioethyl, 2,4,5-T and combinations thereof;

(f) the pyridine class herbicide is selected from the group consisting of aminopyralid, cliodinate, clopyralid, diflufenican, dithiopyr, florpyrauxifen, flufenican, fluroxypyr, halauxifen, haloxydine, picloram, picolinafen, pyriclor, pyroxsulam, thiazopyr, triclopyr, xyloxadine, and combinations thereof;

(g) the cyclohexene oxime class herbicide is selected from the group consisting of alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim, and combinations thereof;

(h) the aryloxyphenoxypropionic class herbicide is selected from the group consisting of chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, metamifop, propaquizafop, quizalofop, quizalofop-P, quizalofop-P-tefuryl, quizalofop-ethyl, trifop, and combinations thereof;

(i) the triazolone class herbicide is selected from the group consisting of amicarbazone, bencarbazone, carfentrazone, flucarbazone, ipfencarbazone, propoxycarbazone, sulfentrazone, thiencarbazone and combinations thereof; and/or

(j) the uracil class herbicide is selected from the group consisting of bromacil, isocil, lenacil, terbacil, benzfendizone, butafenacil, epyrifenacil, flupropacil, saflufenacil, tiafenacil, and combinations thereof.

8. The combination as claimed in claim 1, wherein:
   (a) the nitrophenyl ether class herbicide is oxyfluorfen;
   (b) the imidazolinone class herbicide is selected from imazethapyr, imazapic, imazapyr or combinations thereof;
   (c) the organophosphorous class of herbicide is glyphosate;
   (d) the dicarboximide class herbicide is flumioxazin;
   (e) the phenoxyacetic class herbicide is 2,4-D;
   (f) the pyridine class herbicide is triclopyr;
   (g) the cyclohexene oxime class herbicide is clethodim;
   (h) the aryloxyphenoxypropionic class herbicide is haloxyfop;
   (i) the triazolone class herbicide is carfentrazone; and/or
   (j) the uracil class herbicide is saflufenacil.

9. The combination as claimed in claim 1, wherein glufosinate, salts or esters thereof, is present in an amount in the range of 100 to 400 g ai/L, preferably 180 to 380 g ai/L.

10. The combination as claimed in claim 1, wherein:
   (a) the nitrophenyl ether class herbicide present in an amount in the range of 100 to 400 g ai/L;
   (b) the imidazolinone class herbicide present in an amount in the range of 10 to 250 g ai/L or 100 – 1000 g ai/L;
   (c) the organophosphorous class herbicide present in an amount in the range of 200 to 1000 g ai/L;
   (d) the dicarboximide class herbicide present in an amount in the range of 200 – 800 g ai/L;
   (e) the phenoxyacetic class herbicide present in an amount in the range of 200 to 1200 g ai/L;
   (f) the pyridine class herbicide present in an amount in the range of 300 – 1000 g ai/L;

(g) the cyclohexene oxime class herbicide present in an amount in the range of 100 – 400 g ai/L;

(h) the aryloxyphenoxypropionic class herbicide present in an amount in the range of 1 to 250 g ai/L;

(i) the triazolone class herbicide present in an amount in the range of 100 – 800 g ai/L; and/or

(j) the uracil class herbicide present in an amount in the range of 1 – 1000 g ai/L.

11. An herbicidal composition comprising the combination as claimed in claim 1-10, and at least one agrochemically suitable excipient.

12. The composition as claimed in claim 11, wherein the composition is a tank-mix composition.

13. A method of controlling the growth of undesirable vegetation at a locus, the method comprising treating the locus with an herbicidal combination or a composition as claimed in claims 1 – 12.

14. The method as claimed in claim 13, wherein the glufosinate is applied at an application rate of 50 - 350 g ai/h, preferably 100 g ai/h to 250 g ai/h.

15. The method as claimed in claim 13, wherein at least two herbicides are selected from

(a) the nitrophenyl ether class herbicide applied at an application rate of 5-250 g ai/h;

(b) the imidazolinone class herbicide applied at an application rate of 5-200 g ai/h;

(c) the organophosphorous class herbicide applied at an application rate of 100-800 g ai/h;

(d) the dicarboximide class herbicide applied at an application rate of 1 to 200 g ai/h;

(e) the phenoxyacetic class herbicide applied at an application rate of 50 – 400 g ai/h;

(f) the pyridine class herbicide applied at an application rate of 50-500 g ai/h;

(g) the cyclohexene oxime class herbicide applied at an application rate of 1-150 g ai/h;

(h) the aryloxyphenoxypropionic class herbicide applied at an application rate of 1 -150 g ai/h;

(i) the triazolone class herbicide applied at an application rate of 0.5-100 g ai/h; and/or

(j) the uracil class herbicide applied at an application rate of 10-150 g ai/h.

16. An herbicidal combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a pyridine class herbicide and an uracil class herbicide.

17. The combination as claimed in claim 16, wherein the pyridine class herbicide is triclopyr.

18. The combination as claimed in claim 16, wherein the uracil class herbicide is saflufenacil.

19. An herbicidal combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, a phenoxyacetic class herbicide and an uracil class herbicide.

20. The combination as claimed in claim 19, wherein the phenoxyacetic class herbicide is 2,4-D.

21. The combination as claimed in claim 19, wherein the uracil class herbicide is saflufenacil.

22. An herbicidal combination comprising glufosinate, salts or esters thereof, or L-glufosinate, salts or esters thereof, and two herbicides selected from the imidazolinone class herbicides.

23. The combination as claimed in claim 22, wherein the imidazolinone herbicides are imazapic and imazapyr.

5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN2022/050921

A. CLASSIFICATION OF SUBJECT MATTER

A01N 39/04 (2006.01) ***A01N 43/40 (2006.01)*** ***A01N 43/50 (2006.01)*** ***A01N 43/54 (2006.01)*** ***A01N 57/20 (2006.01)*** ***A01P 13/00 (2006.01)***

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: PATENW, Registry, CASFORM, Agricola CAplus, BIOSIS, CABA, Google
IPC/CPC Marks: A01N39/04, A01N43/40, A01N43/50, A01N43/54, A01N43/653, A01N57/20
Keywords: glufosinate, imazethapyr, carfentrazone, 2,4-D, triclopyr, saflufenacil, imazapic, imazapyr, ternary, combination, example, eleusine, brachiaria, volunteer soybean, amaranth, spermacoce, borreria, synergy, and other like terms and registry numbers.
Applicant/Inventor: Google, CAplus and internal databases provided by IP Australia.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
4 January 2023	04 January 2023
Name and mailing address of the ISA/AU	**Authorised officer**
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustralia.gov.au	Lloyd James AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61 2 6283 2335

INTERNATIONAL SEARCH REPORT C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		International application No. **PCT/IN2022/050921**
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 20180007901 A1 (BASF SE) 11 January 2018 Paragraphs [0146], [0236], [0267]-[0293] and Table 11	1-3, 5-15 & 19-21
X	Albrecht, A. J. P. et al., 'Efficacy of imazapic/imazapyr and other herbicides in mixtures for the control of *Digitaria insularis* prior to soybean sowing', Agronomía Colombiana, 2020, vol. 38, no. 3, pages 350-356 Abstract, Table 1	1, 2, 4-15 & 22-23
X	WO 2019142045 A1 (UPL LTD) 25 July 2019 Page 10 lines 6-8, Example 1, Table 1	1-3, 5-15
X Y	CN 111165509 A (ANHUI YUANJING CROP PROT CO LTD) 19 May 2020 Examples Examples	1-3, 5-15 16-18
X Y	CN 107318884 A (SHAANXI SUNGER ROAD BIO SCI CO) 07 November 2017 Paragraph [0004], Abstract, Examples and Tables Paragraph [0004], Abstract, Examples and Tables	1-3, 5-15 16-18
X	CN 107439586 A (SHANDONG ZHONGXIN KENONG BIOLOGICAL TECH CO LTD) 08 December 2017 Abstract, Examples and Tables	1-3, 5-15
A	US 20110065579 A1 (SIEVERNICH et al.) 17 March 2011 Table 1	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN2022/050921

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box for Details

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Supplemental Box

Continuation of: **Box III**

This International Application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept.

This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups:

- Claims 16-18 (in full) and claims 1-15 (in part) are directed to herbicidal combinations of glufosinate. The combination of glufosinate with a pyridine class herbicidie and a uracil class herbicide is specific to this group of claims.
- Claims 19-21 (in full) and claims 1-15 (in part) are directed to herbicidal combinations of glufosinate. The combination of glufoinsate with a phenoxyacetic acid class herbicide and a uracil class herbicide is specific to this group of claims.
- Claims 22-23 (in full) and claims 1-15 (in part) are directed to herbicidal combinations of glufosinate. The combination of glufosinate with two herbicides from the imidazolinone class of herbicides is specific to this group of claims.

PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art.

When there is no special technical feature common to all the claimed inventions there is no unity of invention.

In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. The only feature common to all of the claimed inventions and which provides a technical relationship among all three groups is a herbicidal combination containing glufosinate (or a combination containing glufosinate + saflufenacil among groups 1 & 2). However this feature does not make a contribution over the prior art because it is disclosed in:

US 20180007901 (BASF SE) 11 January 2018

Therefore in the light of this document this common feature cannot be a special technical feature. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a posteriori*.

It was considered that search and examination of the second and third inventions required negligible additional search and examination effort over the first invention, and therefore additional search fees were not warranted.

The Applicant should note that amendments to other herbicide class combinations (eg. glufosinate + dicarboximide class + cyclohexene oxime class) may attract additional lack of unity and/or support objections.

INTERNATIONAL SEARCH REPORT Information on patent family members	International application No. **PCT/IN2022/050921**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	**Publication Date**	**Publication Number**	**Publication Date**
US 20180007901 A1	11 January 2018	US 2018007901 A1	11 Jan 2018
		US 10506809 B2	17 Dec 2019
		AR 103410 A1	10 May 2017
		AU 2016208065 A1	27 Jul 2017
		AU 2016208065 B2	22 Aug 2019
		BR 112017015016 A2	23 Jan 2018
		CA 2971674 A1	21 Jul 2016
		CN 107105656 A	29 Aug 2017
		CN 107105656 B	08 Jun 2021
		CO 2017008204 A2	05 Jan 2018
		CR 20170374 A	02 Feb 2018
		EA 201791601 A1	30 Nov 2017
		EP 3244742 A1	22 Nov 2017
		IL 253033 B	31 Mar 2020
		JP 2018502129 A	25 Jan 2018
		JP 6783236 B2	11 Nov 2020
		KR 20170103912 A	13 Sep 2017
		PH 12017501223 A1	15 Jan 2018
		PH 12017501223 B1	15 Jan 2018
		WO 2016113334 A1	21 Jul 2016
		ZA 201705359 B	27 May 2020
WO 2019142045 A1	25 July 2019	WO 2019142045 A1	25 Jul 2019
		AR 114178 A1	29 Jul 2020
		AU 2018402682 A1	30 Jul 2020
		BR 102019000606 A2	30 Jul 2019
		CA 3088096 A1	25 Jul 2019
		CL 2020001874 A1	27 Nov 2020
		CO 2020008743 A2	31 Jul 2020
		CR 20200317 A	19 Oct 2020
		JP 2021510705 A	30 Apr 2021
		JP 7143423 B2	28 Sep 2022
		JP 2022177152 A	30 Nov 2022
		KR 20200110670 A	24 Sep 2020

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT Information on patent family members	International application No. **PCT/IN2022/050921**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	**Publication Date**	**Publication Number**	**Publication Date**
		MX 2020007564 A	03 Sep 2020
		US 2020337310 A1	29 Oct 2020
		UY 38048 A	30 Aug 2019
CN 111165509 A	19 May 2020	CN 111165509 A	19 May 2020
CN 107318884 A	07 November 2017	CN 107318884 A	07 Nov 2017
CN 107439586 A	08 December 2017	CN 107439586 A	08 Dec 2017
US 20110065579 A1	17 March 2011	US 2011065579 A1	17 Mar 2011
		US 9629366 B2	25 Apr 2017
		AR 071858 A1	21 Jul 2010
		AR 109257 A2	14 Nov 2018
		AU 2009248755 A1	26 Nov 2009
		AU 2009248755 B2	09 Apr 2015
		BR PI0913114 A2	04 Aug 2015
		BR PI0913114 B1	26 Dec 2017
		CA 2723310 A1	26 Nov 2009
		CA 2940381 A1	26 Nov 2009
		CA 2940383 A1	26 Nov 2009
		CA 3006377 A1	26 Nov 2009
		CL 2009001251 A1	13 Aug 2010
		CL 2014002173 A1	19 Dec 2014
		CL 2014002174 A1	19 Dec 2014
		CL 2014002175 A1	19 Dec 2014
		CN 102036563 A	27 Apr 2011
		CN 102036563 B	05 Nov 2014
		CR 11796 A	10 Jan 2011
		EA 201001768 A1	30 Jun 2011
		EA 019458 B1	31 Mar 2014
		EP 2315525 A2	04 May 2011
		JP 2011520939 A	21 Jul 2011
		JP 5635977 B2	03 Dec 2014
		MX 2010011981 A	07 Dec 2010
		SG 191594 A1	31 Jul 2013
		TW 201002206 A	16 Jan 2010

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT Information on patent family members	International application No. **PCT/IN2022/050921**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	**Publication Date**	**Publication Number**	**Publication Date**
		US 2017042159 A1	16 Feb 2017
		US 9999223 B2	19 Jun 2018
		US 2017325455 A1	16 Nov 2017
		US 11206830 B2	28 Dec 2021
		US 2022087264 A1	24 Mar 2022
		UY 31837 A	14 Dec 2009
		WO 2009141367 A2	26 Nov 2009
		ZA 201009061 B	26 Aug 2015

End of Annex

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.